Pharmacological and nutritional control of dysbiosis related to CNS disorders: gut-brain axis by Lama, Adriano
 UNIVERSITY OF NAPLES FEDERICO II 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF PHARMACY 
 
 
PhD programme in Pharmaceutical Sciences 
 
 
 
 
PHARMACOLOGICAL AND NUTRITIONAL CONTROL OF 
DYSBIOSIS RELATED TO CNS DISORDERS: GUT-BRAIN AXIS 
 
 
 
PhD student 
ADRIANO LAMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXXI CYCLE (2016-2018) 
Coordinator 
Prof. 
MARIA VALERIA D’AURIA 
Tutor 
Prof. 
GIUSEPPINA MATTACE RASO 
 
   
 Summary 
ABSTRACT	 1	
INTRODUCTION	 7	
1.	 PALMITOYLETHANOLAMIDE	 9	
1.1.	 PEA:	ORIGIN,	STRUCTURE,	AND	ACTIVITY	 9	
1.2.	 PEROXISOME	PROLIFERATOR-ACTIVATED	RECEPTORS	(PPARS):	PPARa	FUNCTIONS	IN	
THE	BRAIN	 11	
1.3.	 PPARa	ACTIVATION	AS	MECHANISM	OF	ACTION	OF	PEA	 15	
1.4.	 PHARMACOLOGICAL	EFFECTS	OF	PPARa	AGONISTS:	FOCUS	ON	PEA	IN	CNS	
DISORDERS	 18	
1.5.	 NEW	FORMULATION	OF	PEA:	ULTRA-MICRONIZED	PEA	 20	
2.	 AUTISM	SPECTRUM	DISORDERS	 23	
2.1.	 DEFINITION,	EPIDEMIOLOGY,	DIAGNOSIS	AND	RISK	FACTORS	 23	
2.2.	 TREATMENTS	OF	ASDS	 27	
2.3.	 GUT-BRAIN	AXIS	IN	ASDS	 29	
3.	 OBESITY-INDUCED	DEPRESSION	 32	
3.1.	 DEPRESSION:	DEFINITION,	EPIDEMIOLOGY,	DIAGNOSIS	AND	RISK	FACTORS	 32	
3.2.	 PATHOGENIC	MECHANISMS	OF	MDD	 36	
3.3.	 DEPRESSION	AND	OBESITY:	A	BIDIRECTIONAL	INTERPLAY	 38	
3.4.	 TREATMENT	OF	MDD	 42	
4.	 MATERIAL	AND	METHODS	 45	
4.1.	 SEX	DIFFERENCES	IN	GUT	MICROBIOTA	OF	BTBR	MICE	 45	
4.1.1.	 ANIMALS	 45	
4.1.2.	 MARBLE	BURYING	TEST	 46	
4.1.3.	 SELF-GROOMING	TEST	 47	
4.1.4.	 SOCIAL	INTERACTION	TEST	 47	
4.1.5.	 IN	VIVO	INTESTINAL	PERMEABILITY	ASSAY	 48	
4.1.6.	 HISTOLOGICAL	ANALYSIS	 49	
4.1.7.	 MICROBIAL	DNA	EXTRACTION,	16S	RIBOSOMAL	DNA	(RDNA)	LIBRARY	PREPARATION	
AND	SEQUENCING	 50	
4.1.8.	 SEQUENCING	DATA	ANALYSIS	 52	
4.1.9.	 QUANTIFICATION	OF	GENE	EXPRESSION	USING	RT-PCR	 54	
4.1.10.	 OTHER	STATISTICAL	METHODS	 54	
4.2.	 PEA	COUNTERACTS	AUTISTIC-LIKE	PHENOTYPE	IN	BTBR	MICE	 56	
 4.2.1.	 ANIMALS	 56	
4.2.2.	 DRUGS	AND	TREATMENT	 56	
4.2.3.	 OPEN	FIELD	LOCOMOTION	TEST	(OFT)	 58	
4.2.4.	 MARBLE	BURYING	TEST	 59	
4.2.5.	 SELF-GROOMING	TEST	 59	
4.2.6.	 THREE-CHAMBERED	SOCIAL	TEST	 59	
4.2.7.	 ELEVATED	PLUS	MAZE	TEST	(EPM)	 59	
4.2.8.	 SERUM	PARAMETERS	 60	
4.2.9.	 MITOCHONDRIAL	PARAMETERS	 60	
4.2.10.	 OXIDATIVE	STRESS	ASSAY	 63	
4.2.11.	 WESTERN	BLOT	ANALYSIS	 64	
4.2.12.	 QUANTIFICATION	OF	GENE	EXPRESSION	USING	RT-PCR	 65	
4.2.13.	 16S	METAGENOMIC	SEQUENCING	AND	DATA	ANALYSIS	 65	
4.2.14.	 STATISTICAL	ANALYSIS	 66	
4.3.	 PEA	LIMITS	HFD-INDUCED	DEPRESSION	 67	
4.3.1.	 ANIMALS	AND	TREATMENTS	 67	
4.3.2.	 BODY	WEIGHT	AND	BODY	GAIN	IN	FAT	 68	
4.3.3.	 OPEN	FIELD	LOCOMOTION	TEST	 69	
4.3.4.	 FORCED	SWIMMING	(FST)	AND	TAIL	SUSPENSION	TESTS	(TST)	 69	
4.3.5.	 NOVEL	OBJECT	RECOGNITION	TEST	(NORT)	 70	
4.3.6.	 SERUM	PARAMETERS	 71	
4.3.7.	 C-FOS	AND	IBA-1	STAINING	 72	
4.3.8.	 QUANTIFICATION	OF	GENE	EXPRESSION	USING	RT-PCR	 73	
4.3.9.	 WESTERN	BLOTTING	 74	
4.3.10.	 16S	METAGENOMIC	SEQUENCING	AND	DATA	ANALYSIS	 75	
5.	 RESULTS	 76	
5.1.	 SEX	DIFFERENCES	IN	GUT	MICROBIOTA	OF	BTBR	MICE	 76	
5.1.1.	 OVERALL	STRUCTURE	OF	GUT	MICROBIOTA	OF	MALE	AND	FEMALE	BTBR	MICE.	 76	
5.1.2.	 GUT	MICROBIOTA	PROFILING	OF	BTBR	FEMALE	AND	MALE	MICE	 78	
5.1.3.	 KEY	PHYLOTYPES	DRIVING	GUT	MICROBIOTA	PROFILES	OF	MALE	AND	FEMALE	BTBR	
MICE	 	 79	
5.1.4.	 ALTERATION	IN	BEHAVIORAL	PHENOTYPE,	INTESTINAL	INTEGRITY,	AND	IMMUNITY	IN	
FEMALE	AND	MALE	BTBR	MICE:	CORRELATION	WITH	GUT	MICROBIOTA	MODIFICATIONS	 82	
5.2.	 PEA	COUNTERACTS	AUTISTIC-LIKE	PHENOTYPE	IN	BTBR	MICE	 88	
5.2.1.	 PEA	REDUCED	REPETITIVE	BEHAVIOUR	AND	INCREASED	SOCIABILITY	IN	BTBR	MICE	 88	
5.2.2.	 PEA	IMPROVES	BDNF/TRKB	SYSTEM,	INCREASING	HIPPOCAMPAL	PPAR-a	
EXPRESSION	 95	
5.2.3.	 PEA	TREATMENT	IMPROVES	HIPPOCAMPAL	MITOCHONDRIAL	FUNCTION	AND	REDUCES	
OXIDATIVE	STRESS	 97	
5.2.4.	 PEA	REDUCES	CENTRAL,	SYSTEMIC	AND	INTESTINAL	INFLAMMATION	 98	
 5.2.5.	 PEA	EFFECTS	ON	GUT	PERMEABILITY	AND	MICROBIOTA	 100	
5.3.	 PEA	LIMITS	HFD-INDUCED	DEPRESSION	 104	
5.3.1.	 PEA	LESSENS	DEPRESSIVE-LIKE	BEHAVIOUR	AND	MEMORY	DEFICIT	 104	
5.3.2.	 PEA	IMPROVES	SERUM	METABOLIC	AND	INFLAMMATORY	PARAMETERS	 105	
5.3.3.	 ACTIVATION	OF	POMC	NEURONS	BY	PEA	IN	ARC	 106	
5.3.4.	 PEA	REDUCES	NEURO-INFLAMMATION	IN	HYPOTHALAMUS	 108	
5.3.5.	 PEA	IMPROVES	BDNF/CREB	SYSTEM	AND	REDUCES	HFD-INDUCED	INFLAMMATION	
IN	HIPPOCAMPUS	 110	
5.3.6.	 PEA	AMELIORATING	EFFECT	ON	HFD-INDUCED	DEPRESSION:	POSSIBLE	INVOLVEMENT	
OF	PPAR-a	 111	
5.3.7.	 PEA	RESTORES	BBB	INTEGRITY	OF	HFD-MICE	HIPPOCAMPUS	 112	
5.3.8.	 PEA	EFFECTS	ON	BDNF/CREB	SYSTEM	IN	PREFRONTAL	CORTEX	OF	HFD	MICE	 113	
5.3.9.				PEA	EFFECTS	ON	GUT	MICROBIOTA	COMPOSITION	 114	
6.	 DISCUSSION	AND	CONCLUSIONS	 120	
6.1	GUT-BRAIN	AXIS	IN	ASDS:	FOCUS	ON	PEA	BENEFICIAL	EFFECTS	 120	
6.2.	PEA	AND	OBESITY-INDUCED	DEPRESSION	 128	
HIGHLIGHTS	 134	
GENERAL	CONCLUSIONS:	PEA	AND	CNS	DISORDERS	 135	
7.	 REFERENCES	 136	

1 
 
Abstract 
 
'Leaky gut' syndrome has attracted much attention in recent years, and 
represents now a complementary/alternative target for several complex 
diseases characterized by this pathological condition. It is often described as 
an increase in the permeability of the intestinal mucosa, allowing bacteria, 
toxic digestive metabolites, bacterial toxins, and small detrimental 
molecules to 'leak' into the bloodstream. The microbiota-gut is an integral 
component of the gut–brain neuroendocrine metabolic axis and any 
microbiota-gut disruption that can occur, could distressed homeostasis and 
share an inflammatory response, affecting distal organs including the brain. 
It has been shown, indeed, that the gut can influence the blood brain barrier 
(BBB) through gastrointestinal-derived hormones, small molecule and 
metabolic co-factor production, or through cytokine synthesis and other 
inflammatory mechanisms. Therefore, the CNS is under constant attack or, 
conversely, advantage from a wide variety of neuro-psychotropic-
modulating microbes, and their metabolites. So, the proper 
neurodevelopment and functioning of the CNS depends from an integrated, 
rather than opposing, cross-talk between gut-gut microbiota and brain. 
Several CNS disturbances were related to gastrointestinal dysfunction and 
'leaky brain', underlining the need of identifying new integrative and multi-
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targeted approaches. These complex diseases, being multifactorial, could 
result, in fact, less responsive to targeted standard drugs, since poorly fits 
‘one-disease one-target’ and ‘one-target one-compound’ paradigms in this 
context.  
Here, we focused on autism spectrum disorders (ASDs) and major 
depressive disorder (MDD), two brain disorders linked to a dysfunction of 
BBB and impacted by immune and inflammatory peripheral stimuli. Our 
aim has been to evaluate the possible therapeutic potential of modulating 
several aspects of these multifactorial disorders, in order to benefit of 
peripheral and central contributions, converging on an improvement of 
overall health. 
To this aim we used BTBR T+tf/J (BTBR) mice model of ASDs and high 
fat diet-induced MDD in young mice, and the possible pharmacological 
modulation by palmitoylethanolamide (PEA) was investigated. 
PEA, is an endogenous N-acyl-ethanolamine, biosynthesized to maintain 
cellular homeostasis when this is challenged by external stressors provoking 
inflammation, neuronal damage and pain. The interaction and activation of 
PPARα has been recognized as the main mechanism of the effects evoked 
by this acylethanolamide. In particular, the analgesic and anti-inflammatory 
effects of PEA were demonstrated to be mediated by PPARα activation, 
since it has no effect in PPARα null mice. 
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Indeed, the discovery of PPARα in distinct areas of the brain, opened a new 
scenario to explore the possible activity of this acylethanolamide in the CNS. 
Recently it has been demonstrated that genetic inactivation of PPARα, 
particularly abundant in the CNS, leads to a behavioral and cognitive 
phenotype reminiscent of that of preclinical models of ASDs, i.e. mouse 
model BTBR T+tf/J (BTBR), which displays an improved repetitive 
behavior when autistic mice are treated with a synthetic PPARα agonist. 
These results, not only indicated a central role for this receptor in 
neurological functions associated with the behavior, but more interestingly 
highlighted PPARα as a potential pharmacological target to lessen ASDs 
symptoms. On the other side PEA activity at intestinal level has suggested a 
possible role of this acylethanolamide in modulating not only gut function, 
such as intestinal transit and permeability, but also gut-brain axis. 
Before evaluating the effect of PEA on BTBR mice, in the first part of this 
PhD programme, we performed a study, also evaluating sex influence, on 
gut microbiota composition, behavioral features, and intestinal integrity, 
inflammatory status and architecture of adult male and female BTBR mice. 
These gender characterizations arise from the well-known different clinical 
features of male and female autistic patients and the need to identify them in 
a mouse model of ASD. 
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Consistently with gut-brain axis hypothesis, we showed that BTBR mice 
presented a profound intestinal dysbiosis compared to control strain, more 
marked in female than in male mice, indicating Bacteroides, 
Parabacteroides, Sutterella, Dehalobacterium and Oscillospira genera as 
key drivers of sex-specific gut microbiota profiles associated with altered 
behavior. Interestingly, we also showed that the dysbiosis was accompanied 
in BTBR mice by increased gut permeability and colon inflammation. 
Therefore, we have considered BTBR mice, as an idiopathic model of autism 
useful to investigate not only the correction of the autistic behavior, but also 
a starting point to investigate whether the reduction of intestinal 
inflammation and integrity, and possibly the restoration of gut microbiota 
balance may ameliorate pathological traits. 
Based on this background, the aim of this study was to investigate the 
pharmacological effects of PEA on autistic-like behaviour of BTBR T+tf/J 
mice and to shed light on the contributing mechanisms. PEA was able to 
revert the altered behavior of autistic mice. This effect was contingent to 
PPARa activation, since was blunted by PPARa blocking or deletion. At 
mechanistic level, PEA restored hippocampal BDNF signaling, improved 
mitochondrial dysfunction and reduced serum, hippocampal and colonic 
inflammation. These beneficial effects were related to the reduction of leaky 
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gut in PEA-treated BTBR mice mediated by increased expression of colonic 
tight junctions. In addition, PEA modulated gut microbiota composition, 
underlining the strong link between gut and brain. 
In last years, the connection between modification in gut microbiota induced 
by obesity and the development of MDD has become more evident. High fat 
feeding causes the production of several inflammatory mediators that can 
compromise colonic epithelial barrier function, with the translocation of 
bacterial metabolites in CNS, evoking deleterious events. The modulation of 
PPARα, mostly expressed in hippocampus, has demonstrated to improve 
synaptic dysfunction and HFD-related pathological events in MDD. 
Here, we have addressed the effects of PEA in a mouse model of HFD-
induced depression, focusing on converging mechanisms involved in its 
activity. In particular, we assessed PEA capability in modulating the gut-
brain axis and ameliorating depressive behavior. The treatment with PEA 
improved the depressive-like behavior and memory deficit, shown by HFD 
animals, impacting on BDNF signaling pathway and reducing 
neuroinflammation, both in hypothalamus, hippocampus and prefrontal 
cortex. These beneficial effects of PEA, as PPARa agonist, were correlated 
to an increased expression of PPARa, its coactivator PGC1a, and the 
downstream gene FGF21. As in BTBR model, here PEA also modulated gut 
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microbiota composition, reducing the amount of endotoxin-producer 
Desulfovibrio and increasing Clostridiales genus relative abundance, and 
consistently Clostridiales-producing metabolites, including short-chain fatty 
acids. 
In conclusion, PEA, a multifunctional compound, can represent a novel 
therapeutic approach for multifactorial disorders, such as ASDs and MDD, 
able to counteract the alteration of central and peripheral pathways involved 
in their onset and progression. 
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Introduction 
 
Autism is a multifactorial disorder, where many genes converge, through 
multiple molecular mechanisms, onto common processes involved in the 
development and function of neural circuits, whose alteration leads and 
sustains the core symptoms of ASDs (1). Evidence based on environmental 
factors, such as infection, gut microbiome alteration, and immunological 
features are also growing, suggesting the involvement of many scenarios 
overlapping in this complex neurodevelopmental pathology. Obviously, 
even if targeted specific treatments would clarify the relevance of the altered 
pathways in ASDs, on the other hand the complex heterogeneity in ASDs 
children population could require a multi-targeted approach. Here, we 
analysed the modulatory effect of PEA on many of the pathways and factors, 
starting from the idea that the abnormalities reported to be at the onset and 
progression of this neurodevelopmental pathology are responsible of brain 
dysfunction and consistently associated in core symptoms of ASDs. 
Depression, as well, has a multifactorial nature, resembling that of other 
complex disorders. Very recently, it has been shown that obesity, in critical 
periods for neurodevelopment and neuronal plasticity, may contribute to 
mood and cognitive disorders, therefore constituting a risk factor for 
developing depression and anxiety. In this case, westernized dietary patterns 
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and dysbiosis seem to contribute to obesity-related CNS complications 
involving gut microbiota, as a mediating factor between peripheral signals 
and the brain. It is conceivable to hypothesise that alteration of gut 
microbiota may contribute to the endocrine, neurochemical and 
inflammatory alterations underlying to gut-brain axis interplay. These 
include dysregulation of the HPA-axis with overproduction of 
glucocorticoids, alterations in levels of neuroactive metabolites (e.g., 
neurotransmitters, short-chain fatty acids) and activation of a pro-
inflammatory milieu that can cause neuroinflammation. Up to date, PEA has 
proven to be a multi-targeted compound: the main pharmacological effects 
of PEA are mediated by the activation of PPARα (2, 3), a transcription factor 
involved in the regulation of gene networks, which control pain and 
inflammation (4). This mechanism is supported by the inhibition of neuronal 
firing (5) and by the stimulation of neurosteroid synthesis, indicating that 
multiple mechanisms contribute to the central effect of PEA (6). 
On the other side, PEA has demonstrated to have a peripheral anti-
inflammatory effect shown both on BTBR mice, reducing cytokine 
production, decreasing the inflammatory state at colonic and systemic levels, 
and in rodent models of obesity where it was able to reduce the overall low-
grade inflammation (7), also impacting on the modulation of gut microbiota. 
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1. Palmitoylethanolamide 
 
1.1. PEA: origin, structure, and activity 
 
The acylethanolamides (AEs) are bioactive fatty molecules, synthetized “on 
demand” from membrane phospholipids (8). The recovery of AEs in several 
tissues and their pharmacological effects on multiple biological pathways, 
have suggested a regulator role of these endogenous molecules in paracrine 
or autocrine functions (9). Known their beneficial effects on nociception, 
lipid metabolism, and inflammation, AEs were initially considered Autacoid 
Local Injury Antagonism Amides (ALIAmides) (10). In last years, several 
research groups supported their possible role as neuromodulators, since AEs 
are produced in various areas of brain, both in physiological and 
pathological conditions (11). Indeed, both AEs are produced during neuronal 
damage, carrying out their neuroprotective activity through both receptor 
and non-receptor specific mechanisms (12). 
Among all AEs, PEA is abundant in central nervous system and only 
recently its biological functions have been clarified (13). As shown by 
Figure 1.1, PEA is biosynthesized from phosphatidylethanolamine (PE) by 
two sequential enzymatic reactions (14, 15). The first reaction is the transfer 
of an acyl-group (palmitic acid) from sn-1 position of phosphatidylcholine 
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(PC) to PE by an N-acyltransferase (NAT), generating N-acyl- PE (NAPE) 
(16). Afterwards, PEA is released from NAPE by a phosphodiesterase of 
phospholipase D (NAPE-PLD) (17). PEA is rapidly catabolized by fatty acid 
amide hydrolase (FAAH) to palmitic acid and ethanolamine (18, 19) or N-
acylethanolamine-hydrolyzing acid amidase (NAAA) in inflammatory 
status (20). Considering that NAAA preferentially hydrolyzes PEA rather 
than other AEs, the use of selective NAAA inhibitors could increase local 
levels of endogenous PEA, resulting anti-inflammatory and analgesic 
molecule (20). From the phospholipid bilayer of the plasma membrane, PEA 
is transported by fatty acid binding proteins or heat shock proteins (21) to 
degrading enzymes or target receptors, such as peroxisome PPARa (22) and 
transient receptor potential vanilloid (TRPV)1 (23). 
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Figure 1.1. The metabolic conversion of PEA. 
 
1.2. Peroxisome proliferator-activated receptors 
(PPARs): PPARa functions in the brain 
 
PPARs are ligand-activated transcription factors called lipid “sensors”, 
owning the key role in lipid and lipoprotein metabolism, energy 
homeostasis, cell proliferation death and differentiation. As shown by 
Figure 1.2, these nuclear receptors include three isotypes: PPARa 
(NR1C1), PPARb/d (NR1C2), and PPARg (NR1C3). PPARs, as other 
members of the nuclear receptor superfamily, have four domains: (i) a N-
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terminal A/B domain, important mediator of PPAR subtype-specificity, 
determining PPAR subtype-specificity and containing a weak ligand-
independent transactivation function called AF-1; (ii) a C domain, highly 
conserved, that binds DNA via a two zinc-finger motif (hallmark of the NR 
superfamily); (iii) a D domain, which is a hinge region; (iv) an E/F domain, 
which is the ligand binding domain (LBD) (24). 
 
 
 
Figure 1.2 (A) Structural superposition of PPARα (white), PPARδ (magenta) and PPARγ 
(cyan). 3D structure of (B) PPARα, (C) PPARδ and (D) PPARγ. 
 
The conformational change of PPARs is induced by different type of fatty 
acids, triggering the transcription of specific genes that encode for several 
metabolic and cellular processes, such as fatty acid b-oxidation and 
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adipogenesis (25). To this purpose, molecules that target PPARs can 
modulate lipid and glucose metabolism, representing excellent therapeutic 
tools for metabolic disorders (26, 27). 
The activity of PPARs is based on the bond with specific DNA sequence 
elements (named PPAR response elements, PPREs), and on regulation of 
gene expression like heterodimers with retinoid X receptors (RXRs) (28-
30). Indeed, the dimerization between specific RXR isotypes (a, b, g) and 
PPARs seems to influence the recognition of target gene promoters (31) 
(Figure 1.3) 
 
 
 
Figure 1.3. PPARs bind RXR to constitute PPRE. Ligands can modulate the transcription 
of target genes. L, ligand; RA. 9-cis-retinoic acid. 
 
It is well known that PPAR-mediated effects are modulated by the 
interaction with several factors, including corepressors and coactivators 
(32). The steroid receptor coactivator 1 and the cAMP response element-
binding (CREB) protein are two pivotal coactivators of PPARs and they own 
histone acetyl transferase activity that induces chromatin decondensation 
14 
 
and target gene activation. Beyond the clear interaction with PPARg, PPARg 
coactivator 1a (PGC-1a) binds PPARa in ligand-dependent manner, 
carrying out cellular functions, such as reactive oxygen species (ROS) and 
fatty acids (FAs) metabolism associated with mitochondrial and 
peroxisomal biogenesis (33-36). These functions are pivotal in counteracting 
CNS disorders, where redox unbalance and lipid dysmetabolism play a 
detrimental role in neurodegeneration. The distribution of PPARa varies in 
different tissues, it is generally expressed at high extent in metabolically 
active ones (liver, heart, skeletal muscle, intestinal mucosa and brown 
adipose tissue) (37), even if studies demonstrated their occurrence in brain 
(38, 39). In particular, Moreno et al. (40) described deeply the distribution 
of PPARs and RXRs in rodent brain. PPARa shows several functions in the 
brain: regulation of lipid metabolism (shortening of VLCFAs, use of FAs as 
metabolic fuel, biosynthesis of PUFAs) (41, 42); management of ROS 
metabolism (increase of antioxidant systems and induction of H2O2-
producing enzymes) (43-45); neural cell proliferation, differentiation and 
apoptosis (46-49); modulation of dopaminergic, glutamatergic and 
cholinergic neurotransmission (50-52); cognitive and memory function, 
spatial learning, emotionality (53-55); modulation of pain pathways (4, 56-
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59); modulation of fasting and satiety responses via hypothalamus-pituitary 
axis and peripheral glucose homeostasis (60-63). 
Despite the hippocampus does not produce energy from fat metabolism, 
PPARα has been identified in different subfields of this tissue in rodents (64, 
65). Interestingly, PPARα knockdown mice showed a reduction of several 
plasticity-associated molecules (NR2A, NR2B, GluR1 and Arc), but not 
voltage-gated ion channel ones, suggesting a crucial role of PPARα in 
hippocampal plasticity (64). In the same study, the authors demonstrated that 
PPARα agonists induced the activation of CREB (pivotal in synaptic 
plasticity) promoter in hippocampal neurons from wild type mice and not 
from PPARα knockout ones (64). All these findings highlight PPARα 
involvement in brain functions. 
 
1.3. PPARa activation as mechanism of action of 
PEA 
 
The anti-inflammatory, analgesic and neuroprotective effects of PEA are 
related to the involvement of both central and peripheral nervous system 
targets (2-4). In particular, different cell types involved in resolving chronic 
pain and inflammation (immune cells, microglia and neurons) synthetize and 
metabolize PEA (66). 
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PEA is an endocannabinoid-like molecule and, as such, was originally 
considered a CB2 agonist (67). Furthermore, PEA activity has been also 
associated to its capability in increasing half-life and therefore its effects on 
CB or TRPV1 (68-70), the so-called “entourage effects” due to PEA 
competitive inhibition of AEA hydrolysis on FAAH (71) and/or direct 
allosteric effect on TRPV1 (72, 73). Therefore, PEA is not a merely 
“classical” endocannabinoid because its pharmacological effects reside 
outside of a strict interaction with CB receptors. Beyond the interactions of 
PEA with orphan receptors, such as G protein-coupled receptor (GPR) 55 
and GPR119 (74-77), the main role of pharmacological activity of PEA is 
related to PPARα activation (13). Indeed, PEA increases properties of 
calcium-activated intermediate (IKCa) and big-conductance potassium 
(BKCa) potassium channels via a PPARα dependent non-genomic 
mechanism, leading to a fast reduction of neuronal firing (3). In addition, as 
demonstrated by Sasso et al. (78) in acute or persistent pain mice model, the 
activation of PPARα, through a genomic mechanism, increases the 
expression of steroidogenic acute regulatory protein (StAR) and cytochrome 
P450 side-chain cleavage (CYP450scc), leading to the transport of 
cholesterol into mitochondria and its metabolic conversion into 
pregnanolone. The subsequent increase of allopregnanolone production 
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induce a positive allosteric activation of aminobutyric acid (GABA)-A 
receptors, an increase in Cl- fluxes and a reinforcing effect on the reduction 
of neuronal firing. Furthermore, the anti-inflammatory effects of PEA seem 
to be correlated with PPARa capability in preventing the nuclear 
translocation of NF-kB and repressing the expression of pro-inflammatory 
proteins (i.e. TNF-a, IL-1b), limiting the recruitment of immune cells (79) 
(Figure 1.4) 
 
Figure 1.4. Direct and indirect mechanisms of action of PEA. (A) the competitive 
inhibition of AEA metabolism by FAAH; (B) allosteric activity on TRPV1 and its 
desensitization; (C) genomic and non-genomic mechanisms dependent on PPARα. 
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1.4. Pharmacological effects of PPARa agonists: 
focus on PEA in CNS disorders 
 
On the basis of these observations, it is conceivable that targeting PPARa 
can represent the basis for novel therapies in the treatment of acute and 
chronic CNS pathologies. Indeed, several studies highlighted the beneficial 
effects of different PPARa agonists in improving neuroinflammation, 
underlying neurodegenerative disease and neuropsychiatric disorders (80). 
Among endogenous ligands of PPARa, OEA and PEA own several 
neuroprotective functions (81-83). In rat model of transient focal cerebral 
ischemia, PEA achieved a significant neuroprotective effect by reducing 
infarcted tissue size (84). Moreover, this molecule was able to protect 
neuronal cells from oxidative stress and alter the expression levels of kinases 
involved in neuroprotection (85). Koch et al (86) demonstrated also that 
PEA protected dentate gyrus granule cells from excitotoxically-induced 
neuronal damage, activating PPARa and not PPARg in microglial cells and 
hippocampal neurons. Consistently, our research group demonstrated that 
PEA reduced oxidative stress in astroglial cells through PPARa-triggered 
biosynthesis of allopregnanolone (87). The role of PEA in regulating the 
complex systems involved in inflammatory and adaptive immune response, 
acute and chronic pain is now well understood (13). Concerning pathogenic 
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mechanisms of pain, PPARa has been shown to be overexpressed in rat 
spinal cord after peripheral noxious stimulation (56). Furthermore, 
D’Agostino et al. (4) demonstrated that intracerebroventricular 
administration of PEA significantly reduced the expression of the pro-
inflammatory mediators, such as COX-2 and iNOS, in dorsal root ganglia 
following carrageenan-induced intraplantar oedema. The obligatory role of 
PPARa was confirmed by the loss of anti-nociceptive effects in PPARa 
knockout mice. 
In neurodegenerative disorders, such as Parkinson’s Disease (PD) and 
Alzheimer Disease (AD), PPARa agonists, and in particular PEA, seem to 
have a therapeutic effect. In MPTP-treated mice, an animal model of PD, 
PEA reversed MTPT-induced motor deficits in PPARa-dependent manner, 
reducing microglial activation, astrocyte number and S100b overexpression 
(88). Avagliano et al. (89) demonstrated that PEA levels are drastically 
reduced in post-mortem brain samples from AD patients. Consistently, both 
in in vitro and in vivo AD model, PEA was able to improve pathological 
features (90, 91). 
The beneficial effects of PEA in mood disorders, especially in depression, 
are still overlooked. To date, only two preclinical studies and double-blind, 
randomized and placebo-controlled trial suggested the hypothesis that PEA 
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can reduce a depressive-like behavior (92-94). In particular, in a mouse 
model of anxiety/depression induced by corticosterone administration, a 
formulation of PEA and luteolin improved hippocampal neurogenesis and 
neuroplasticity. Yu et al. (92) demonstrated that oral PEA produced a 
significant reduction in immobility time in both tail suspension test (TST) 
and forced swimming test (FST). Only in a clinical study, recently 
published, the association of PEA with citalopram effectively improves 
symptoms of patients (predominantly male gender) with major depressive 
disorder, even if further investigations are needed (94). 
Among neurodevelopmental disorders, autism spectrum disorder (ASD) is 
characterized by alterations in the brain's endocannabinoid system as 
demonstrated by Kerr et al. (95). In particular, these authors showed that in 
rat valproic acid model of autism there was a reduction of PPARα and 
GPR55 expression in the frontal cortex and PPARγ and GPR55 expression 
in the hippocampus while CB1 or CB2 receptor expression was not altered 
in all any brain regions. In another recent study, Bertolino et al (96) showed 
the beneficial effects of an association of PEA and luteolin in VPA mouse 
model and in an autistic child, even if the mechanisms of action keep still 
unclear. 
 
1.5. New formulation of PEA: ultra-micronized PEA 
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Although the excellent pharmacological activity, PEA drawbacks are based 
on its poor solubility and bioavailability, due to its lipophilic nature. 
Moreover, apart from dissolution-rate-limited PEA absorption, another limit 
is particle size, inversely related to PEA bioavailability. All these drawbacks 
have prompt to improve PEA pharmacokinetic features. The micronization 
has been an excellent strategy to this aim, producing microparticles <10 μm 
(97, 98), in order to increase surface area and rate of dissolution (99), 
together with a reduction of absorption variability (100). Indeed, ultra-
micronized PEA (PEA-um) has demonstrated an improved efficacy when 
administered per os compared to standard PEA powder administration. 
Recently, Petrosino et al. (101) have published an article focused not only 
on the absorbability of PEA-um and naïve PEA, but, interestingly, also on 
their distribution in peripheral and central tissues in physiological and 
inflammatory conditions. Notably, the authors demonstrated an increased 
plasma concentration by ultramicronization of PEA, in fact, differently from 
naïve PEA administration, PEA-um (30 mg/kg per os) to healthy animals 
resulted detectable in the bloodstream already after 5 min, with a peak 
plasma concentration of 5.4 ± 1.87 pmol/ml. This pharmacokinetic profile 
was even more favorable in inflamed animals, showing an increase of PEA-
um concentration in plasma and inflamed tissues (including spinal cord). 
22 
 
Ultra-micronized PEA, provided by Epitech Group, is produced by the air-
jet milling technique, where powder is slowly inserted into a jet-mill 
apparatus endowed with a chamber of 300 mm in diameter that operates with 
“spiral technology” driven by compressed air. The high number of collisions 
that occur between particles as a result of the high level of kinetic-not 
mechanical-energy produces sub-micron-sized crystals. 
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2. Autism spectrum disorders 
 
2.1. Definition, epidemiology, diagnosis and risk 
factors 
 
The term autism spectrum disorders (ASDs) describes a group of early-
appearing social communication deficits and repetitive sensory-motor 
patterns due to multiple converging causes (102). ASDs, over time, have 
become from barely and rare disorders of childhood onset to studied and 
recognized lifelong conditions with heterogeneous features. Although 
autistic individuals are very different from each another, the core features 
are based on two areas without any cultural, racial, ethnical and socio-
economical differences: impaired social interaction and repetitive 
stereotyped motor behaviors (103). ASDs represent an economic burden, 
mainly for autistic patients with low functionality due to expensive provision 
of support: in 2014, its cost estimated $3020 for health care and $14 061 for 
aggregate non-health care, including $8610 for school education (104). In 
2010, the global prevalence of ASDs was about 1% (105), even if a more 
recent review estimated an increase up to 5% in developed countries (106). 
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Since there are no reliable biomarkers, ASD diagnosis is based on American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-5 criteria, considering specific behavioral traits (102). To 
identify an ASD patient, a person must show evidence of complications, in 
each of three social communication subdomains and/or in two of the four 
different stereotyped and repetitive sensory-motor behaviors (Table 2.1) 
 
Persistent deficits in social 
communication and social 
interaction 
Restricted, repetitive patterns of 
behavior, interests, or activities 
Deficits in social–emotional 
reciprocity (e.g. abnormal social 
approach and failure of normal 
back-and-forth conversation; or 
reduced sharing of interests, 
emotions, or affect) 
Stereotyped or repetitive motor 
movements, use of objects, or 
speech (e.g. simple motor 
stereotypies, lining up toys, or 
flipping objects) 
Deficits in non-verbal 
communicative behaviors (e.g. 
poorly integrated verbal and non-
verbal communication, 
abnormalities in eye contact and 
body language, or deficits in 
understanding and use of gestures) 
Insistence on sameness, inflexible 
adherence to routines, or ritualized 
patterns of verbal and non-verbal 
behavior 
(e.g. extreme distress at small 
changes, difficulties with 
transitions, or rigid thinking 
patterns) 
Deficits in developing, maintaining, 
and understanding 
relationships (e.g. difficulties 
adjusting behavior to suit various 
social contexts; or difficulties in 
sharing imaginative play or making 
friends) 
Highly restricted, fixated interests 
that are abnormal in 
intensity or focus (e.g. strong 
attachment to or 
preoccupation with unusual 
objects) 
 Hyperreactivity or hyporeactivity 
to sensory input, or unusual 
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interests in sensory aspects of the 
environment (e.g. apparent 
indifference to pain or temperature, 
or adverse responses to specific 
sounds or textures) 
 
Table 2.1. The description of ASD signs and symptoms in DSM-5. 
 
Early diagnosis plays a crucial role to minimize the possible intellectual 
disabilities, reported later in underestimated and undertreated ASD adults. 
In addition to screening instruments, such as several standardized 
assessment tools (e.g. STAT, ADOS, ADI-R and DISCO), other strategies, 
including an increased awareness of ASDs in the family and community and 
an easy access to specific services, can improve the quality of life of ASD 
patients. The difficulty in ASD diagnosis is getting worse by accompanying 
comorbidities (attention-deficit hyperactivity disorder, social anxiety, 
generalized anxiety and phobias) (107). This concern is mainly worth for 
females, rather than males, who can be underdiagnosed due to the high 
occurrence of comorbidities (e.g. depression and severe anxiety) that hide 
and mask ASD symptoms (108). 
Many risk factors for ASDs have been described and they are divided in two 
main types: environmental and genetic. The advanced parental age (³40 
years for mothers and ³50 years for fathers) and a short interpregnancy 
intervals have been independently associated to an increased risk for ASD 
26 
 
onset in children (106, 109). The use of antibiotics and the consequent 
perturbations of gut microbiota during pregnancy are a potential risk factors 
for infantile ASD (110). Furthermore, some non-optimal conditions of 
mothers (excessive weight gain, hypertension, nosocomial infections or 
autoimmune disease) can contribute the development of ASDs (111). 
Although results from different studies have to be clarified, some links with 
air pollutants and maternal stressors during pregnancy have been found 
(106). Beyond maternal conditions, preterm birth (<32 weeks), low 
birthweight (<1500 g), small-for-gestational-age status, and large-for-
gestational age status (>95th birthweight percentile) represent other 
important risk factors (112, 113), even if the reasons of their involvement 
keep still unclear. The administration of many drugs in pregnant mothers has 
been associated to an increased risk of ASDs. Christensen et al. (114) 
demonstrated that a prenatal valproic acid exposure increased the probability 
of ASD in offspring. In addition, de Theije et al. (115) also in rodents 
demonstrated that this in utero valproic acid exposure induced gut 
inflammation, altered microbiota, and ASD-like behavioral abnormalities in 
male offspring. Other studies did not confirm the previous belief in 
antidepressant-induced ASD effects (116). In last years, media and no-vax 
organizations strongly supported the association between ASDs and 
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vaccination, but, to date, no scientific evidence has clearly demonstrated 
their link (117). 
Beyond the environmental factors, the genetic risk has assumed an even 
more important role in ASD pathogenic mechanisms. Tick et al. (118) 
showed that ASDs can be inherited in 74-93% of cases. The first evidence 
of this link between ASDs and genetic was the development of autistic 
behavior in patients affected by rare genetic syndromes, such as fragile X 
syndrome (119). Following studies demonstrated also that the mutations of 
more than 100 genes are involved in ASD risk, indicating an objective 
obstacle in ASD diagnosis through genetic screening (120). 
 
2.2. Treatments of ASDs 
 
ASDs are a group of complex diseases and as such, its treatment represents 
a complicated challenge. To date, psychological interventions are the most 
important tools to manage these disorders (103). Weitlauf et al. (121) 
reported that early parent-mediated interventions to coach how to interact 
with ASD children give immediate beneficial effects on autistic traits. 
Another approach is the naturalistic behavioral developmental interventions 
that include the most well-known Applied Behaviour Analysis (ABA). This 
strategy considers the presence of adult teacher or therapist who works one-
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to-one with ASD child and teaches some developmental abilities, such as 
language, imitation and cognitive skills. Several meta-analyses 
demonstrated the good improvements by these interventions with a duration 
time of 15-20 hours or more per week (122). For school-age children and 
adolescents, the most common behavioral interventions are social skill 
groups (123). Although all these psychological interventions are necessary, 
unfortunately, their beneficial effects are, in any case, limited. 
The pharmacological treatment of ASDs is limited to reduce symptoms and 
not to counteract ASDs itself. In two randomized controlled trials, 
risperidone (124) and aripiprazole (125) showed an improvement of 
irritability or agitation in ASD young patients, even if these beneficial 
effects were not recognized in all children. In addition, both drugs are mixed 
with dopamine-receptor and serotonin-receptor antagonists or partial 
agonists, while no other medications are used in ASDs (126). The concern 
in using a pharmacological treatment for ASDs is the development of 
adverse events that include sedation, weight gain, and an increased hearth 
risk. 
Although basic science research has discovered about pathogenic 
mechanisms of ASDs, the clinical implications remain few. 
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2.3. Gut-brain axis in ASDs 
 
ASDs are neuropsychological diseases with a marked peripheral component. 
Indeed, beyond the social and psychological pattern, ASD patients show 
gastrointestinal symptoms with underlying pathogenic mechanisms that are 
not completely clarified yet. Alterations in gut integrity and modifications 
of its microbiota represent features of autistic outline and the interaction 
between brain and gut is achieved by influx of microbiota signals (gut 
hormones and microbial metabolites) in CNS, via the immune system, the 
vagus nerve and other host microbe interactions (127). Therefore, the 
scaffold of this gut-brain axis is constituted by the CNS, the autonomic 
nervous system (both sympathetic and parasympathetic branches), the 
neuroendocrine and neuroimmune systems, the enteric nervous system 
(ENS) and, the gut microbiota (Figure 2.1). All these features represent 
main characters of a complex network, where a bidirectional communication 
system between gut microbes and CNS played a key role for host 
homeostasis (128). Indeed, genes within the gut microbiota, termed the 
microbiome are capable of producing a myriad of neuroactive compounds, 
playing a pivotal role in shaping cognitive networks underlying social 
cognition, emotion, and behavior (129). During the development, brain 
neural circuits and gut microbiota co-evolve and possible alterations of gut 
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microbiota composition influence the normal growth of CNS 
neurotransmission, particularly for serotonergic system (130). Indeed, 
alterations of integrity in both gut epithelium barrier and BBB, reported in 
ASD patients (131, 132), can cause the translocation of bacterial 
metabolites, inducing immunoreactions that can activate the vagal system or 
directly influence CNS activity, impacting on neuronal plasticity and 
consequently on mood and behavior (133, 134). In rats, the lack of gut 
microbiota colonization leads to a reduced sociability, an increased anxiety-
like behavior and alterations of neurophysiology compared to control mice 
with no pathogen bacteria colonization (135, 136).  
Several clinical studies highlighted the link between dysbiosis and ASDs. 
Tomova et al. (137) showed a reduction of Bacteroidetes/Firmicutes ratio in 
ASD patients, while Strati et al. (138) demonstrated a significant reduction 
in relative abundance of phylum Bacteroidetes in autistic subjects. In 
contrast, Son et al. (139) did not find any alteration in gut microbiota 
composition in a study comparing fecal microbiota in ASD children and 
neurotypical siblings by qPCR. These conflicting evidences and the small 
scale of preclinical studies demonstrated the difficulty to outline a distinctive 
gut microbiota composition in ASDs. 
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Figure 2.1. The scaffold of the gut-brain axis. The interaction between brain and gut is 
achieved by influx of microbiota signals, such as gut hormones and microbial metabolites, 
in CNS, via the immune system, the vagus nerve and other host microbe interactions.  
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3. Obesity-induced depression 
 
3.1. Depression: definition, epidemiology, diagnosis 
and risk factors 
 
Major depressive disorder (MDD) is a debilitating disease associated to 
reduced quality of life, medical morbidity, and mortality (140). Indeed, in 
2013, it was considered the second leading cause of disability in all countries 
(141). The DSM-V identifies MDD when a person suffered from at least one 
discrete depressive episode lasting at least two weeks, characterized by 
changes in mood, interests and pleasure and by alterations of cognitive and 
vegetative spheres (102) (see Figure 3.1). 
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Figure 3.1. Definition of MDD according to DSM-5. 
 
MDD represents a worldwide burden because about 6% of the adult 
population shows depressive episodes, mostly in women (about 2-fold) 
(142). In both sexes, MDD onset is approximately at 25 years of age and the 
range of increased risk is constituted by mid-to-late adolescence to early 40s 
(143). Furthermore, MDD prevalence was found to be similar between high- 
and low- and middle-income countries, highlighting that MDD does not 
represent a “modern-world” disease (Figure 3.2) (144). 
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Figure 3.2. Worldwide prevalence of MDD. The overall estimates in high-income 
countries (5.5%) and low- and middle-income countries (5.9%) do not significantly differ. 
 
The progress of MDD is essentially variable and it depends on its remission 
and chronicity. The prediction of an ill-fated course can be facilitated by 
higher symptom severity, other psychiatric comorbidities and the occurrence 
of childhood trauma (145). In population-based samples, the mean episode 
of MDD lasts between 13 and 30 weeks with a recovery of approximately 
70–90% of patients within 1 year (146, 147), even if, in outpatient care 
settings, the remission rate can drastically decrease to 25% (148, 149). 
Furthermore, the recurrence of MDD is high, as about 80% of patients 
experiences at least another depressive episode during lifetime (150). Both 
in healthy people and other no-MDD patients, depression increases the 
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mortality risk by 60-80%, and its contribution of all-cause mortality is 10% 
(151, 152). 
As mentioned above, MDD is diagnosed in patients who develop several 
symptoms distinguished from normal sadness or bereavement that endures 
at least 2 weeks (102). Beyond depressive mood, it needs only two of six 
symptoms such as appetite disturbances, loss of energy, reduced self-esteem, 
sleep disturbances, poor concentration or hopelessness. The persistent 
depressive disorder is a chronic disease characterized by depressive 
symptoms for more than 2 years. Once MDD diagnosis is made, the disorder 
can be classified by different specifiers (see Scheme 3.1). 
Being MDD a multifactorial disease no established mechanisms can explain 
all aspects involved in its onset. The contribution of genetic factor is 
estimated to about 35%, highlighted more in family and twin-based studies 
rather than in single-nucleotide polymorphism-based estimates from 
genome-wide association studies (GWAS) (153). On the other side, 
environmental factors, such as sexual, physical or emotional abuse, 
contribute to the development of MDD. Indeed, epidemiological studies 
correlated the onset of MDD with stressful events (loss of employment, 
chronic or life-threatening health problems, financial insecurity, exposure to 
violence, separation and bereavement) usually occurred in the year 
preceding onset and disease itself (154). However, not only recent events 
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but also childhood-occurred ones, including physical and sexual abuse, 
psychological neglect, exposure to domestic violence or early separation 
from parents due to death, are clearly responsible of MDD (155). 
 
3.2. Pathogenic mechanisms of MDD 
 
The oldest known pathogenic mechanism of MDD is based on the lack of 
balance in the serotonergic, noradrenergic and dopaminergic systems (156). 
Indeed, for many years, MDD research focused on the metabolism of their 
neurotransmitters, such as noradrenaline, serotonin and dopamine, and their 
effect on both presynaptic and postsynaptic receptors (157). 
Following studies moved their focus on connection between MDD and 
endocrine pathways. The hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction represents the center of this link. Indeed, early-life stress 
induces the activation of corticotropin-releasing hormone (CRH)-containing 
neural circuits in several animal studies (158). This involvement has been 
confirmed by clinical studies, showing how children subjected to sexual or 
physical abuse showed a marked activation of HPA axis when exposed to 
standardized psychosocial stressors or through endocrine tests trying to stop 
HPA activity (159). Moreover, increased levels of cortisol, whose 
production is generally controlled by the hypothalamus, represented a risk 
factor for the onset of MDD in clinical studies (160, 161). 
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The immune system is another major character involved in the physiological 
stress-sensing pathways and interacts directly and indirectly with HPA, the 
autonomic nervous system and CNS in pathogenic mechanisms of MDD. 
Indeed, once peripheral cytokines reach and cross the BBB, they activate 
CNS-resident cells, such as astrocytes, microglia and neurons. In a clinical 
study, patients who received cytokine treatments, such as IL-2 or interferon-
g, for hepatitis or cancer therapy, showed higher rate to develop depressive 
episodes (162). Other meta-analyses confirmed these findings, showing high 
levels of serum cytokines, such as tumor necrosis factor (TNF)-a and IL-6 
in MDD patients (163, 164). The increased levels of circulating cortisol and 
inflammatory cytokines can affect brain function, through the disruption of 
neuroplasticity and the reduction of neurogenesis, as demonstrated by low 
levels of the neurotrophin, brain-derived neurotrophic factor (BDNF) (165). 
Taken together, all these evidences underline how all those biological 
pathways, taking part into the so-called psycho-immune-neuroendocrine 
(PINE) network (Figure 3.3) are involved in MDD. 
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Figure 3.3. The psycho-immune-neuroendocrine (PINE) network of MDD. Beyond the 
impairment of CNS, the hyperstimulation of HPA axis is another pathological feature of 
MDD. Moreover, this pathological condition activates the immune system, increasing levels 
of circulating cytokines and triggering a low-grade chronic inflammation. Once MDD 
becomes chronic, both HPA hyperactivity and inflammation might converge towards an 
alteration of autonomic nervous system (ANS), contributing to MDD comorbidities, such 
as cardiovascular and metabolic disorders. 
 
3.3. Depression and obesity: a bidirectional interplay 
 
Among several risk factors, different studies highlighted the bidirectional 
association between obesity and depression (166, 167). Faith et al. (168) 
examined different studies to understand whether the association 
“depression-to-obesity” is stronger than “obesity-to-depression” or vice 
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versa. These authors reported a more significant influence of obesity to 
depression than the opposite (80% vs 53%). 
The general mechanisms that try to explain the obesity-induced depression 
are two: 
• Obesity and MDD share fundamental biological mechanisms 
(inflammatory, neuroendocrine, metabolic and gut-related patterns), 
and the alterations of these systems induced by obesity can lead to 
MDD; 
• Chronic psychological stress related to lack of self-confidence 
induced by body-image consciousness leads to dysregulation of 
PINE network, triggering the onset of MDD. 
According to this paradigm, the pathophysiological features of obesity, such 
as low-grade inflammation, ANS unbalance, leptin and ghrelin changes, and 
dysbiosis play a pivotal role as underlying pathogenic mechanisms of MDD. 
The obesity-induced systemic inflammation is characterized by the increase 
of serum levels of pro-inflammatory cytokines, such as IL-6 and TNF-a, 
that stimulate the microglial proliferation and astrocyte dysfunction with 
consequent neuroinflammation, mainly in areas that lack an effective BBB, 
including hypothalamic arcuate nucleus (ARC) (169). The ARC is strongly 
connected not only with other regions of the hypothalamus, but also with 
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other brain areas, such as mesolimbic dopamine system, hippocampus, 
orbitofrontal cortex, nucleus accumbens, striatum and prefrontal cortex, 
regulating motivation and reward pathways (170). Thus, beyond the effects 
on feeding signals, the inflammation in ARC can potentially impair 
cognitive function (Figure 3.4). 
Moreover, neuroinflammation can trigger the PINE network to reach the 
critical threshold for MDD onset, even if molecular mechanisms keep still 
unclear. 
Leptin and ghrelin are central regulators in the PINE network. Beyond their 
key role in food intake, these molecules are implicated in mood regulation 
(171-173). Leptin interacts with its receptor, particularly abundant in ARC, 
and, activating the proopiomelanocortin (POMC) neurons and suppressing 
neuropeptide Y (NPY) and agouti-related protein (AgRP) ones, reduces 
feeding behavior. HFD-induced obesity induces a leptin resistance, 
characterized by high systemic levels of leptin and reduced central leptin 
sensitivity. This detrimental condition can lead to a reduced neuroprotection 
and onset of MDD (174-176). 
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Figure 3.4. Possible mechanism of cognitive dysfunction induced by obesity. 
HFD/obesity induce the HPA dysfunction that can alter other brain areas, such as 
hippocampus, reducing neurogenesis and inducing neuronal apoptosis. 
 
The contribution of the change in gut microbiota induced by obesity in the 
development of MDD has been analyzed in several studies. As mentioned 
above, high fat diet consumption causes the production of several 
inflammatory mediators that can compromise colonic epithelial barrier 
function, inducing the so-called “leaky gut” (177). This increased 
permeability allows the entrance of immunogenic molecules, such as LPS 
(178), in the systemic circulation, whose occurrence has been recognized in 
both animal (179) and human (180) affected by depression. Moreover, long-
term consumption of a Western-style HFD, constituted by low levels of 
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fiber, may result in profound reduction of short chain fatty acids (SCFAs), 
endogenous molecules with marked anti-inflammatory and neurogenesis 
activity (181). The intestinal dysbiosis induced by obesity, may promote 
depression through the modulation of hippocampal BDNF. Indeed, Bercik 
et al. (182) demonstrated that the administration of antimicrobials was 
responsible of BDNF reduction in mice hippocampus, while colonization of 
germ-free mice with gut microbiota from other specific pathogen free mice 
increased the expression of neurotrophin. 
 
3.4. Treatment of MDD 
 
Given the complexity and high prevalence of MDD, its prevention is 
fundamental to limit it. These strategies include the strengthening protective 
factors, such as the increase of social support, and the reduction of prodromal 
symptoms, limiting them before that they overcome the disease threshold. 
Indeed, a meta-analysis demonstrated the reduction of depressive symptoms 
(21%) in MDD patients who received a preventive intervention (183). 
The treatment of MDD depends on the severity of symptoms and include 
two main strategies: psychotherapy and pharmacotherapy. Mild depressive 
episodes could be treated only with psychotherapy, but when the grade 
worsens, a pharmacological treatment alone or in combination with 
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medication and psychotherapy should be adopted, two weeks after the 
beginning of symptoms (184). Several meta-analyses did not show any 
consistent difference among different types of psychotherapy (185-187). 
The pharmacological treatment of MDD comprises the use of monoamine-
based antidepressant drugs, capable to stimulate an adaptive neuronal 
response against MDD central perturbations (Figure 3.5), although the exact 
biomolecular mechanisms of action are not completely clarified. In addition, 
the wider choice of selective serotonin reuptake inhibitors (SSRIs) or 
serotonin–norepinephrine reuptake inhibitors (SNRIs) than that of classical 
antidepressant drugs is due to better adverse-effect profile rather than 
efficacy. However, SSRIs and SNRIs are also characterized by several 
adverse effects, such as headache, insomnia, gastrointestinal symptoms, 
dizziness, sexual dysfunction, weight gain and sleep disturbances (188). 
Among new therapeutic approaches for MDD, several compounds are under 
investigation, such as neurokinin 1 antagonists, glutamatergic system 
modulators, anti-inflammatory agents, opioid tone modulators and opioid κ 
antagonists, hippocampal neurogenesis-stimulating treatments and anti-
glucocorticoid therapies (140). 
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Figure 3.5. Actual pharmacological strategies for MDD treatment. 
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4. Material and Methods 
 
4.1. Sex differences in gut microbiota of BTBR mice 
 
4.1.1. Animals 
 
C57Bl/6J (C57) and BTBR T + tf/J (BTBR) inbred strains of mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and a 
colony was established and maintained. For the study, 24 fully symptomatic 
BTBR mice (12 months of age, 12 for gender) and 24 C57 control mice (12 
months of age, 12 for gender) were housed in the same room under standard 
12-h light/12-h dark cycle with free access to water and standard laboratory 
chow diet. Mice were from different litters and housed by gender separately 
2/3 per cage. Before killing and prior to serum and sample collection, 
animals, kept overnight fasted, were anesthetized by enflurane and 
euthanized by an intraperitoneal injection of a cocktail of ketamine/xylazine. 
As suggested by the animal welfare protocol, all efforts were made to 
minimize animal suffering and to use only the number of animals necessary 
to produce reliable scientific data. All procedures involving animals and 
their care were conducted in conformity with international and national law 
and policies (EU Directive 2010/63/EU for animal experiments, ARRIVE 
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guidelines and the Basel declaration including the 3R concept). The 
procedures reported here were approved by the Institutional Committee on 
the Ethics of Animal Experiments (CSV) of the University of Naples 
“Federico II” and by the Ministero della Salute under protocol no. 0022569-
P-20/12/2010. 
 
4.1.2. Marble burying test 
 
For the performing of all behavioral tests, we considered the book of Bayley 
et al. (189). Male and female BTBR and C57 (n=12 each group) were 
individually placed in a plastic container (46 cm long x 24 cm wide x 21 cm 
deep) with 5 cm of clean woodchip bedding (Northeastern Products, NY). 
The plastic container was placed in a room used for behavioral testing. Once 
a mouse was gently allocated into the test container, a wire lid was placed 
on top and undisturbed mice were allowed to freely explore the container for 
30 min, as habituation time. Twenty-four hours later, 20 glass marbles (1.5 
cm in diameter) were placed on top of clean bedding, arranged in five rows 
of four and mice located into plastic cages for 30 minutes. After this 
experimental time, each mouse was removed from the testing container and 
replaced to their home cage. When a threshold of 75% coverage for each 
marble was observed, it was considered buried and recorded. After the test, 
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the marbles were thoroughly cleaned and new bedding was used for each 
mouse. The same animals tested for marble burying test were also examined 
for grooming behavior. 
 
4.1.3. Self-grooming test 
 
Mice were individually placed in an empty plastic cage (28 cm wide × 17 
cm long × 12 cm high) and were freely to explore the arena for 20 minutes. 
The first 10 min were necessary for a habituation time. During the second 
phase, a trained observer, sat approximately 1.6 m from the test cage, timed 
the cumulative period that mice spent in self-grooming. Grooming behavior 
included head washing, body grooming, genital/tail grooming and paw and 
leg licking. After the test, the cage was thoroughly cleaned. After self-
grooming test, the same animals were tested for sociability test. 
 
4.1.4. Social interaction test 
 
Social interaction was examined using the three-chambered apparatus as 
previously described (190-192). The apparatus (60 x 40 cm) has two 
doorways that divide it into a three chambers apparatus (20 x 40 cm each). 
Number of entries and time spent in each chamber were automatically 
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detected by a video camera coupled with a video-tracking software (Any-
maze, Stoelting). The sociability test was preceded by 5-min habituation 
session where each mouse is restrained in the center of the middle chamber. 
After this phase, a novel sex, strain and age matched mouse (not used in later 
testing and previously habituated) is placed in one side of the chamber under 
an enclose cup while the other side contained an empty cup. During this 
sociability phase, walls between the compartments were removed and the 
tendency to approach a novel mouse was compared with tendency to 
approach a novel object is monitored and recorded. Each mouse was free to 
explore all three chambers for 10 minutes and both sides were alternated 
between the left and right chambers across subjects. 
 
4.1.5. In vivo intestinal permeability assay 
 
In vivo intestinal permeability assay was performed for a subset of mice 
using fluorescein isothiocyanate-labeled dextran (FITC-dextran) method, as 
previously described (193). Before the beginning of the test, food and water 
were withdrawn for 6 hours, after which mice (n=5, each group) were 
administrated by gavage with FITC labeled dextran 4000 (Sigma-Aldrich, 
Milan, Italy), as permeability tracer (60 mg/100 g body weight). After 24 
hours blood of all animals was collected by intracardiac puncture and 
49 
 
centrifuged (3000 rpm for 15 min at RT). Then plasma FITC-dextran 
concentration was determined (excitation, 485 nm; emission, 535 nm; HTS-
7000 Plus-plate-reader; Perkin Elmer, Wellesley, MA, USA), using a 
standard curve generated by serial dilution of the tracer. 
 
4.1.6. Histological analysis 
 
Colonic tissues of male and female mice of both strains (n=3) were removed, 
washed and then fixed in paraformaldehyde (4% v/v; Carlo Erba, Italy) for 
12 hours. These samples were dehydrated, embedded in paraffin and cut into 
5 μm thick sections before being stained with hematoxylin-eosin (H&E; 
Carlo Erba, Italy). Images were obtained by a Leica DFC320 video camera 
(Leica, Milan, Italy) connected to a Leica DM RB microscope using the 
Leica Application Suite software V2.4.0. 
Colon sections were analyzed by the same pathologist in a blinded manner 
to evaluate their structure and architecture. Histopathology was quantified 
following: a) the severity of inflammatory cell infiltration was evaluated by 
percentage of leukocyte density in lamina propria area and estimated in a 
high-power field (HPF) representative of the section (0 for no signs of 
inflammation, 1 for minimal < 10%, 2 for mild 10–25% with scattered 
neutrophils, 3 for moderate 26–50%, 4 for marked > 51% with dense 
50 
 
infiltrate); b) The extent of the inflammation was estimated as expansion of 
leukocyte infiltration (0 for none, 1 for mucosal, 2 for mucosal and 
submucosal and 3 for mucosal, submucosal and transmural level). 
 
4.1.7. Microbial DNA extraction, 16S ribosomal DNA (rDNA) 
library preparation and sequencing 
 
Freshly evacuated fecal pellets were kept directly in a sterile microtube one 
day before the sacrifice of mice and stored at -80 °C until assayed. Bacterial 
genomic DNA was extracted from frozen fecal samples using the QIAamp 
DNA Stool Mini Kit (Qiagen) according to manufacturer’s instructions. 
DNA concentration was measured fluorometrically using Qubit dsDNA BR 
assay kit (Invitrogen) and quality was assessed by spectrophotometric 
measurements with NanoDrop (ThermoFisher Scientific Inc). Samples were 
stored at -20 °C until processed for amplification. It is well documented that 
various compartments of the gastro-intestinal tract harbour different 
bacterial populations. We chose to analyze readly accessible fecal samples 
for gut microbiome analyses mainly because fairly representative of the 
whole gastro-intestinal tract, with exception of some surface-adherent 
bacterial species. Sequencing samples were prepared according to the 
protocol 16S Metagenomic Sequencing Library Preparation for Illumina 
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Miseq System with some modifications. The V3–V4 regions of the 16S 
rDNA gene were amplified starting from 200 ng of DNA template in a 
reaction volume of 50 μ L containg 1x Fast start High Fidelity Reaction 
Buffer, 5 μ M of each primer, 0.2 nM of dNTPs, 3 mM MgCl2, and 2 U 
FastStart High Fidelity PCR System (Roche Applied Science). PCR was 
performed using the following cycles conditions: an initial denaturation step 
at 95 °C for 2 min, followed by 30 cycles of 95 °C for 30 s, 55 °C for 45 s, 
72 °C for 55 s and ended with an extension 
step at 72 °C for 5 minutes; products were visualized by electrophoresis on 
1.2% agarose gel. After a purification step with Agencourt AMPure XP 
(Beckman Coulter Inc), the amplicons were indexed with 10 subsequent 
cycles of PCR using the Nextera XT Index Kit (Illumina). Each PCR 
reaction contained 10 μ L of amplicons from first PCR, 5 μl index 1 primer 
(N7xx), 5 μl index 2 primer (S5xx), 5 μ l 1x Fast start High Fidelity Reaction 
Buffer, 6 μL MgCl2 (3 mM), 1 μ L dNTPs (0.2 nM), 0.4 μ L FastStart High 
Fidelity PCR System (2U) and 17.6 μ l PCR grade water. PCRs were carried 
out, visualized using gel electrophoresis and subsequently cleaned as 
described above. 
Library sizes were assessed using a Bioanalyzer DNA 1000 chip (Agilent 
technologies) and quantified with Qubit. Normalized libraries were pooled, 
52 
 
denatured with NaOH, then diluted to 10pM and combined with 25% (v/v) 
denatured 10pM PhiX, according to Illumina guidelines. Sequencing run 
was performed on an Illumina Miseq system using v3 reagents for 2 × 281 
cycles. 
 
4.1.8. Sequencing data analysis 
 
V3-V4 16S rDNA FASTQ paired-end reads were quality filtered and 
assembled using PEAR (194). Only sequences showing average PHRED 
score ≥ 30, read length between 400 and 500 bp and overlapping regions 
between mate-pair end of at least 40 nucleotides were retained in this step. 
Passing filter sequences were then processed with PRINSEQ (195) in order 
to obtain FASTA and quality files for further analyses. Metagenomic 
analyses on the resulting data were conducted using Quantitative Insights 
Into Microbial Ecology (QIIME, version 1.8.0) (196). 16S sequences were 
used to pick OTUs at 97% of sequences similarity from Greengenes 16S 
gene database (GG, may 2013 version) (197) with a closed reference-based 
OTU picking method. The GG database was used to taxonomically classify 
the identified OTUs and to compute their distribution across different 
taxonomic levels. To avoid sample size biases in subsequent alpha and beta 
diversity analyses, a sequence rarefaction procedure was applied using a 
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maximum depth of 32,228 sequences/sample. To assess sampling depth 
coverage and species heterogeneity in each sample, alpha diversity metrics 
were employed on rarefied OTU table using Good’s coverage, Observed 
species and Shannon’s diversity index. A two-sample permutation t-test, 
using 999 Monte Carlo permutations to compute p-value, was performed to 
compare the alpha diversities between sample groups. OTUs diversity 
among sample communities (beta diversity) was assessed by applying 
unweighted Unifrac distances. Statistical significance of beta diversities was 
assessed on unweighted UniFrac distances matrixes using ANOSIM method 
(198) with 999 permutations. Statistical differences in OTUs frequencies 
across sample groups at different taxonomic levels were assessed using 
nonparametric Kruskal-Wallis test. Next, two analyses were applied on OTU 
tables generated by QIIME to identify key OTUs that discriminate female 
and male BTBR mice from their respective controls: Metastats comparison 
using the online interfaces (199) and LDA Effect Size analysis (LEfSe) 
(200). Only those OTUs reported by both methods to be significantly 
different between the two groups (p < 0.05 for Metastats, LDA > 2 and p < 
0.05 for LEfSe) have been considered as key discriminatory OTUs. Key 
genera that discriminate female and male BTBR mice from their respective 
controls were identified applying only LEfSe. 
 
54 
 
4.1.9. Quantification of gene expression using RT-PCR 
 
Total RNA was extracted from tissues using TRIzol Reagent (Bio-Rad 
Laboratories), according to the manufacturer’s instructions. cDNA was 
synthesized using a reverse transcription kit (NucleoSpin®, MACHEREY-
NAGEL GmbH & Co, Düren, Germany) from 4 μg total RNA. PCRs were 
performed with a Bio-Rad CFX96 Connect Real-time PCR System 
instrument and software (Bio-Rad Laboratories). The PCR conditions were 
15 min at 95 °C followed by 40 cycles of two-step PCR denaturation at 94 
°C for 15 s, annealing at 55 °C for 30 s and extension at 72 °C for 30 s. Each 
sample contained 500 ng cDNA in 2X QuantiTect SYBRGreen PCR Master 
Mix and primers pairs to amplify zonuline-1 (Tjp1), occludin (Ocln), TNF-
α (Tnfa), interleukin-6 (Il6), interleukin-10 (Il10), CD11c (Itgax) (Qiagen, 
Hilden, Germany), in a final volume of 50 μl. The relative amount of each 
studied mRNA was normalized to GAPDH as housekeeping gene, and data 
were analyzed according to the 2-ΔΔCT method. 
 
4.1.10. Other statistical methods 
 
Marble burying, self-grooming, plasma FITC-dextran, gene expression data 
were analyzed by two-way ANOVA with strain and sex as factors; social 
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approach behavior results were analyzed by three-way ANOVA with 
chamber, strain and sex as factors. Multiple comparisons were performed 
using Bonferroni’s post-hoc test. Pearson correlation test was used to assess 
the eventual relationship between the amount of key genera and behavioral 
scores, intestinal permeability and inflammation. In this study results were 
considered statistically significant at p-value < 0.05. Significant differences 
were indicated in figures by *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. ANOSIM and permutation t-test were performed using 
QIIME scripts, all other analyses were performed using R 3.2.050. Bar plots 
were created by using GraphPad Prism 6.0. 
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4.2. PEA counteracts autistic-like phenotype in 
BTBR mice 
 
4.2.1. Animals 
 
Male C57Bl/6J (B6), B6.129S4-SvJae-Pparatm1Gonz PPARa null (KO) 
and BTBR T + tf/J (BTBR) (3-4 months old) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA) and colonies maintained in our 
animal facility genotyped according to supplier webpage 
(http://jaxmice.jax.org), using the RedExtract kit (Sigma–Aldrich, Italy). 
All animals were housed in groups in a room maintained at 22°C, on a 12 
h:12 h light:dark cycle, with ad libitum access to water and standard 
laboratory chow diet. To minimalized litter effects, we used mice from at 
least 5 different litters in each experiment. All experimental procedures were 
carried out in compliance with the international and national law and policies 
(EU Directive 2010/63/EU for animal experiments, ARRIVE guidelines and 
the Basel declaration including the 3R concept) and approved by Italian 
Ministero della Salute. 
 
4.2.2. Drugs and treatment 
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Ultra-micronized PEA (PEA-um®; Epitech Group, Italy) and GW6471 (N-
((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl) phenyl)prop-1-enyl) 
amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl) 
propanamide), a PPARα antagonist (GW; Tocris, Bristol, UK) were 
dissolved in PEG400, Tween 80 and sterile saline (Sigma-Aldrich, Milan, 
Italy) to obtain a final concentration of PEG400 and Tween 80 of 20 and 
10% v/v, respectively and injected at a volume of 10 ml/kg body weight. 
BTBR, KO and control B6 mice were daily intraperitoneal-injected (i.p.) for 
10 days with vehicle, PEA (10 or 30 mg/kg), and/or GW (1mg/kg). When 
BTBR mice were co-treated with PEA and GW, the antagonist was injected 
30 min before PEA administration. Testing began at ages 3-4 months, on 
day 9th, one hour after the last injection. In details, behavioural tasks 
described below were conducted in the same mice from 5 different litters, in 
a battery on two separate days (9th-10th) according to Paylor, Spencer (201), 
with sufficient intervals between tests and in a sequence that begins with the 
least stressful quick observational tests followed by the more stressful 
complex tasks, except for the evaluation of locomotor activity and anxiety 
behaviour (elevated plus maze and open field test) that were conducted on a 
separate cohort of mice. All experiments and data analyses were performed 
58 
 
by blinded operators to genotype, when possible, and treatment. The 
experimental protocol is summarized in Figure 4.2.1. 
 
 
Figure 4.2.1. Experimental protocol BTBR and PEA. 
 
4.2.3. Open field locomotion test (OFT) 
 
The OFT represents and index of general locomotor activity and anxiety 
behaviour of animals (202). Mice were placed into the center of a clear 
square grey (40x40 cm) open-field arena and allowed to explore for 10 
minutes. We measured the locomotor activity and the time spent in the centre 
quadrant and peripheral frame. The movements of mice were recorded by 
the infrared video camera and analysed by Any-maze-tracking software 
(Stoelting Co., Wood Dale, IL, U.S.A.). 
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4.2.4. Marble burying test 
 
In marble burying test, we choose BTBR and C57 (n=10 each group) and 
proceeded as in previous work. 
 
4.2.5. Self-grooming test 
 
The same subjects tested in marble burying test were also examined for 
grooming behavior, as reported in previous work. 
 
4.2.6. Three-chambered social test 
 
The same subjects tested in marble burying and self-grooming tests were 
also examined for social approach behavior, as reported in previous work. 
 
4.2.7. Elevated plus maze test (EPM) 
 
The elevated plus maze (EPM) is test suitable for evaluation of mice anxiety, 
based on the test animal aversion to open spaces. The maze (Ugo Basile 
apparatus, Gemonio, Italy) comprised four arms (5 cm in width and 35 cm 
in length), with two opposing arms enclosed from the sides by black walls 
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(20 cm in height), defined as closed arms, whereas the other two arms 
remained unclosed (open arms). The intersection area for all four arms, 
defined as center, represented the access sector to all four arms. Mice were 
placed individually in the center of the apparatus, facing an open arm and 
allowed to explore the maze for 5 min detected by the Any-maze tracking 
software. We measured the number of entries in open and closed arms and 
time spent in these zones. An arm entry is defined as entry of all four paws 
into an arm. The main variable commonly associated to an ‘anxiety-like’ 
state is the percent time spent in the closed arm. 
 
4.2.8. Serum parameters 
 
Before sacrifice, mice were anesthetized by enflurane and blood was 
collected by cardiac puncture. Serum samples were obtained by 
centrifugation at 1500 x g at 4°C for 15 min. Serum TNF-α, IL-1β and IL-6 
were measured using commercially available ELISA kits (Thermo Fisher 
Scientific, Rockford, IL), following the manufacturer’s instructions. 
 
4.2.9. Mitochondrial parameters 
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Mitochondria isolation and oxygen consumption (polarographically 
measured using a Clark-type electrode) were carried out. Briefly, the livers 
were freshly collected and washed in a medium containing 220 Mm 
mannitol, 70 mM sucrose, 20 mM N2-(hydroxyethyl) piperazine-N-2-
ethanesulfonic acid (HEPES) (pH 7.4), 1 mM-EDTA, and 0.1 % w/v fatty 
acid free BSA. Tissue fragments were homogenized with the above medium 
(1:4, w/v) in a Potter Elvehjem homogenizer (Heidolph, Kelheim, Germany) 
set at 500 rpm (4 strokes/min). The homogenate was centrifuged at 1000 gav 
for 10 min and the resulting supernatant fraction was again centrifuged at 
3000× g for 10 min. The mitochondrial pellet was washed twice and finally 
resuspended in a medium containing 80mMKCl, 50 mM HEPES (pH 7.0), 
5 mM KH2PO4, and 0.1% w/v fatty acid free BSA. The protein content of 
the mitochondrial suspension was determined by the method of Hartree 
using BSA as the protein standard (203). Isolated mitochondria were then 
used for the determination of respiratory parameters. 
Oxygen consumption was measured in the presence of substrates and ADP 
(state 3), in the presence of substrates alone (state 4) and their ratio 
(respiratory control ratio, RCR) were calculated. The substrates used for 
liver respiration were 10 mM succinate + 3.75 μM rotenone or 40 μM 
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palmitoylcarnitine + 2.5 mM malate for the determination of fatty acid 
oxidation rate. 
The degree of coupling was determined in the liver by applying equation by 
Cairns et al. (204): degree of coupling = 𝟏	 −	(𝐉𝐨)𝐬𝐡/(𝐉𝐨)𝐮𝐧𝐜 where (Jo)sh 
represents the oxygen consumption rate in the presence of oligomycin that 
inhibits ATP synthase, and (Jo)unc is the uncoupled rate of oxygen 
consumption induced by carbonyl cyanide 
trifluoromethoxyphenylhydrazone (FCCP), which dissipates the 
transmitochondrial proton gradient. (Jo)sh and (Jo)unc were measured as 
above using succinate (10 mmol/L) rotenone (3.75 μmol/L) in the presence 
of oligomycin (2 μg/mL) or FCCP (1 μmol/L), respectively. Aconitase 
activity was measured spectrophotometrically (at 412 nm). Determination of 
aconitase specific activity was carried out in amedium containing 30mM 
sodium citrate, 0.6mM MnCl2, 0.2 mM NADP, 50 mM TRIS-HCl pH 7.4, 
and two units of isocitrate dehydrogenase. The formation of NADPH was 
followed spectrophotometrically (340 nm) at 25°C (205). The level of 
aconitase activity measured equals active aconitase (basal level). Aconitase 
inhibited by ROS in vivo was reactivated so that total activity could be 
measured by incubating mitochondrial extracts in a medium containing 50 
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mM dithiothreitol, 0.2 mM Na2S, and 0.2 mM ferrous ammonium sulphate 
(206). 
Carnitine-palmitoyl-transferase (CPT) activity was followed 
spectrophotometrically as CoA-sH production by the use of 5,5'-dithiobis 
(nitrobenzoic acid) (DTNB) and as substrate palmitoyl coA 10 μM. The 
medium consisted of 50 mM KCl, 10 mM Hepes (pH 7.4), 0.025% Triton 
X-100, 0.3 mM DTNB, and 10–100 pg of mitochondrial protein in a final 
volume of 1.0 ml. The reaction was followed at 412 nm with 
spectrophotometer, and enzyme activity was calculated from an E412 = 
13,600/ (M X cm). The temperature was maintained at 25°C. Aconitase 
activity was measured spectrophotometrically (412 nm). Determination of 
aconitase specific activity was carried out in a medium containing 30mM 
sodium citrate, 0.6mM MnCl2, 0.2 mM NADP, 50 mM TRIS-HCl pH 7.4, 
and two units of isocitrate dehydrogenase. The formation of NADPH was 
followed spectrophotometrically (340 nm) at 25°C. The level of aconitase 
activity measured equals active aconitase (basal level). Superoxide 
dismutase (SOD)-specific activity was carried out according to Flohe and 
Orting (207). 
 
4.2.10. Oxidative stress assay 
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The levels of reactive oxygen species (ROS) were determined as described 
by Montoliu et al. (208). Briefly, fresh hippocampal homogenate was diluted 
in 100 mM potassium phosphate buffer (pH 7.4) and incubated with a final 
concentration of 5 μM dichlorofluorescein diacetate (Sigma–Aldrich) in 
dimethyl sulfoxide for 15 min at 37°C. The dye-loaded samples were 
centrifuged and the pellet suspended in 100 mM potassium phosphate buffer 
and incubated for 60 min at 37°C. The fluorescence measurements were 
performed with a HTS-7000 Plus-plate-reader spectrofluorometer (Perkin 
Elmer, Wellesley, Massachusetts, USA) at 488 nm for excitation and 525 
nm for emission wavelengths. ROS stress was quantified from the 
dichlorofluorescein standard curve in dimethyl sulfoxide (0–1 mM). 
 
4.2.11. Western blot analysis 
 
Hippocampus was homogenized in lysis buffer (50 mM Tris–HCl, pH 7.4; 
1 mM EDTA; 100 mM NaCl; 20 mM NaF; 3 mM Na3VO4; 1 mM PMSF 
with 1 % (v/v) Nonidet P-40; and protease inhibitor cocktail). Lysates were 
centrifuged at 20,000 g for 15 min at 4 °C. Protein concentrations were 
estimated using bovine serum albumin as a standard in a Bradford reagent 
assay. Proteins were separated on SDS-PAGE, transferred to nitrocellulose 
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membranes, and incubated with the following primary antibodies: PPARα 
(cat no P0369, Sigma Aldrich), 1: 500; Bdnf (cat no sc-546, Santa Cruz), 
1: 200; pCREB (cat no 9196, Cell Signaling Technologies (CST), MA, 
USA), 1:1000; CREB (cat no 4820, CST) 1: 2000; β-actin (Sigma Aldrich), 
1:1000. The signals were visualized with the ECL system (Pierce) by Image 
Quant (GE Healtcare, Milan, Italy). The protein bands were 
densitometrically analyzed with the Quantity One software (Bio-Rad 
Laboratories). 
 
4.2.12. Quantification of gene expression using RT-PCR 
 
RNA extraction and following Real Time-PCR analysis were performed as 
in previous work, even if, here, we tested primers pairs to amplify Tjp1, 
Ocln, Tnfa, Il6, Il1b, peroxisome proliferator-activator receptor a (Ppara), 
brain-derived neurotrophic factor (Bdnf), neurotrophic receptor tyrosine 
kinase 2 (Ntrk2) (Qiagen, Hilden, Germany), in a final volume of 50 μl. 
 
4.2.13. 16S metagenomic sequencing and data analysis 
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Fecal samples were collected from a subset of six mice randomly selected 
from each group and quickly stored at -80°C. Fecal microbiota was studied 
as reported above.  
 
4.2.14. Statistical analysis 
 
Data are presented as mean ± SEM. All the experiments were analysed using 
analysis of variance (ANOVA) for multiple comparisons followed by 
Bonferroni’s post hoc test, using GraphPad Prism (GraphPad software, San 
Diego, CA, USA). Statistical significance was set at p<0.05 in all the 
statistical analyses. 
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4.3. PEA limits HFD-induced depression 
 
4.3.1. Animals and treatments 
 
Standard chow diet had 17% fat, without sucrose while high fat diet (HFD), 
a diet that induces obesity (DIO, Harlan Teklad) had 45% of energy derived 
from fat, 7% of sucrose. Standard and HFD contained 3.3 kcal/g and 5.24 
kcal/g, respectively. Ultra-micronized PEA was provided by Epitech Group 
Research Labs and it was suspended in carboxymethyl cellulose (1.5%) for 
oral administration. 
Male C57BL/6J mice (Harlan, Italy) at 6 weeks of ages, were housed in 
stainless steel cages in a room kept at 22±1˚C with a 12:12 hours lights-dark 
cycle. After weaning, young mice were randomly divided into three groups 
(at least 10 animals for each group) as follows: control group (STD) 
receiving chow diet and vehicle per os by gavage; HFD group receiving 
vehicle; HFD group treated with PEA (HFD+PEA, 30 mg/kg/die per os). 
The treatments started after 12 weeks of feeding with HFD and continued 
for 7 weeks. The experimental protocol is outlined in Fig. 4.3.1. All 
procedures involving the animals were carried out in accordance with the 
Institutional Guidelines and complied with the Italian D.L. no.116 of 
January 27, 1992 of Ministero della Salute and associated guidelines in the 
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European Communities Council Directive of November 24, 1986 
(86/609/ECC). All animal procedures reported herein were approved by the 
Institutional Animal Care and Use Committee (CSV) of University of 
Naples Federico II under protocol no. 2011–0129170. 
 
Figure 4.3.1. Experimental protocol HFD and PEA. 
 
4.3.2. Body weight and body gain in fat 
 
During the experimental period, body weight of mice was assessed one time 
for week. At the end of the experimental protocol, before sacrifice, 
bioelectrical impedance analysis was applied to determine fat body 
composition assessment using BIA 101 analyzer, modified for the mouse 
(Akern, Florence, Italy). Fat free mass was calculated using bioelectrical 
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impedance analysis and fat mass content was determined as the difference 
between body weight and fat-free mass. 
 
4.3.3. Open field locomotion test 
 
After 6 weeks of PEA treatment, STD, HFD and HFD+PEA mice were 
undergone to OFT, as previously reported in BTBR+PEA experiment. After 
OFT, the same animals were tested for forced swimming, tail suspension 
and novel object recognition tests. 
 
4.3.4. Forced swimming (FST) and Tail suspension tests (TST) 
 
The forced swimming and tail suspension tests represent the most used 
procedures which seek the evaluation of depressive-like behaviors in 
rodents, because immobility induced by exposure to an inescapable aversive 
situation (forced swimming or tail suspension) denotes an index of 
resignation (189). 
The method of the FST was developed previously (209) and was 
subsequently modified (210-213). Briefly, mice were placed in a 
polymethylpentene cylinder (diameter 137 mm; height 200 mm) filled with 
25 °C water to a depth of approximately 150 mm for 15 min as a pre-test 
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(pre-FST). After 24 h, mice were forced to swim again for 10 minutes and 
were recorded the entire time using a video camera. Immobility time was 
measured for the last 8 minutes of the swim period by observers in blinded 
manner. Immobility was defined as when mice stopped swimming and 
floated on the water. 
For TST, we followed an established protocol (214, 215). Briefly, mice were 
acclimated to the behavior room for 1 h and then suspended by their tails to 
the edge of a shelf 55 cm above the floor. Adhesive tape (17 cm long) 
attached the tail (approximately 1 cm from the tip of the tail) to the shelf. 
The movements of mice were recorded by a camera for 7 minutes, even if 
immobility time was measured for the last 6 minutes. Mice were considered 
static when they hung passively and completely motionless. 
 
4.3.5. Novel object recognition test (NORT) 
 
NORT is a behavioral test which allow to evaluate a memory recognition 
deficit induced by an acute restraint stress (216). The test was done with 
habituation, familiarization and novel object recognition phases as described 
previously with some modifications (217). Mice were habituated for 10 
minutes a day before the test plexiglass box (40 × 25 × 18 cm). During the 
familiarization phase, two identical objects were placed in the opposite 
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corners of the test box and the subject mice were allowed to explore for 
10 min. At the end of this time, mice were kept back to their home cages. 
After 24 h, mice were placed in test box and kept undisturbed to explore a 
novel object for 5 minutes. During the recognition phase, one of the familiar 
objects were replaced with a new object different in shape and color. The 
tests were automatically detected by a video camera coupled with a video-
tracking software (Any-maze, Stoelting). Object exploration was defined 
when the mouse was sniffing in close proximity to the object but not when 
the head was in another direction. After each trial, the arena floor and the 
objects were wiped with 70% ethanol to eliminate odour cues for the next 
subject. 
 
4.3.6. Serum Parameters 
 
STD and HFD mice, treated or not with PEA for 7 weeks, were sacrificed 
after overnight fasting. Blood collected by cardiac puncture was centrifuged 
at 2500 rpm at 4˚C for 12 minutes, and sera were stored at -80˚C for later 
biochemical and hormonal determinations. Alanine amino transferase 
(ALT), triglycerides (TG) were measured by colorimetric enzymatic method 
using commercial kits (SGM Italia, Italy and Randox Laboratories ltd., 
United Kingdom). Serum IL-1, (Thermo Scientific, Rockford, IL, USA), 
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TNF-α, and monocyte chemoattractant protein-1 (MCP-1) (Biovendor 
R&D, Brno, Czech Republic), adiponectin and leptin (B-Bridge 
International Mountain View, CA) and fasting insulin (cat. no. EZRMI-13K; 
Millipore) concentrations were measured using commercially available 
ELISA kits. 
 
4.3.7. C-fos and Iba-1 staining 
 
After overnight fasting, mice were anesthetized and transcardially perfused 
with 0.9% saline with heparin followed by fixative (4% paraformaldehyde, 
15% picric acid, 0.1% glutaraldehyde in PBS). Brains were collected, post 
fixed overnight, and coronal sections were taken at every 50 μm. For c-fos 
staining, slides were washed and incubated with the rabbit anti-cfos antibody 
(Santacruz, 1:2000), and the chicken anti-GFP antibody (Life Technologies 
Corporation, 1:5000) in PB containing 4% normal goat serum, 0.1% glycine, 
and 0.2% Triton X-100 for 24 h at room temperature. For Iba-1 staining 
slides were washed and incubated with the mouse anti-Iba-1 antibody 
(Millipore, 1:1000) in PB containing 4% normal goat serum, 0.1% glycine, 
and 0.2% Triton X-100 for 24 h at room temperature. After several washes 
with PB, all sections were incubated in the secondary antibodies (for c-fos, 
biotinylated goat anti-rabbit, and for Iba-1, goat anti-mouse immunoglobulin 
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G [IgG]; 1:250 in PB; Vector Laboratories and goat antichicken Alexa-fluor 
488; 1:200 in PB; Life Technologies) for 2 h at room temperature, then 
rinsed in PB five times, 10 min each time. Sections were then mounted with 
VectaShield antifade (Vector Laboratories). Fluorescent images of five to 
seven brain sections were captured with confocal microscope and analyzed 
by imaging Software (Image J), that can be downloaded from this link: 
https://imagej.nih.gov/ij/download.html. 
 
4.3.8. Quantification of gene expression using RT-PCR 
 
Total RNA was extracted using TRIzol Reagent (Bio-Rad Laboratories) and 
following a specific RNA extraction kit (NucleoSpin®, MACHEREY-
NAGEL GmbH & Co, Düren, Germany), according to the manufacturer’s 
instructions. cDna was synthesized using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) from 2 µg total RNA. PCRs were 
performed with a Bio-Rad CFX96 Connect Real-time PCR System 
instrument and software (Bio-Rad Laboratories). The PCR conditions were 
15 min at 95°C followed by 40 cycles of two-step PCR denaturation at 94°C 
for 15 s, annealing extension at 55°C for 30 s and extension at 72°C for 30 
s. Each sample contained 500 ng cDNA in 2X QuantiTect SYBRGreen PCR 
Master Mix and primers pairs to amplify zonuline-1 (Tjp1), occludin (Ocln), 
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TNF-α (Tnfa), NF-kB (Nfkb1), interleukin-1b (Il1b), PPARa (Ppara), 
BDNF (Bdnf), Trkb (Trkb), (Qiagen, Hilden, Germany), in a final volume 
of 50 μl. The relative amount of each studied mRNA was normalized to 
GAPDH as housekeeping gene, and data were analyzed according to the 2-
ΔΔCT method. 
 
4.3.9. Western blotting 
 
Hippocampus and prefrontal cortex from each mouse were homogenized 
and total protein lysates were subjected to SDS-PAGE. The blot was 
performed by transferring proteins from a slab gel to nitrocellulose 
membrane at 240 mA for 60 minutes at room temperature. The filter was 
then blocked with 1X PBS and 5% nonfat dried milk for 60 minutes at room 
temperature and probed with rabbit polyclonal antibody against anti-
phospho-CREB and anti-CREB (dilution 1:1000; Cell Signaling 
Technology, Danvers, MA, USA), anti-BDNF (dilution 1:1000; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), anti-PPARa (diluition 1:200,  Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA), anti-PGC1a and anti-FGF21 
(1:1000, Elabscience, Bethesda, USA). Western blot for Actin (1:5000; 
Sigma-Aldrich, Milan, Italy) was performed to ensure equal sample loading. 
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4.3.10. 16S metagenomic sequencing and data analysis 
 
Fecal samples were collected from a subset of six mice randomly selected 
from each group and quickly stored at -80°C. Fecal microbiota was studied 
as reported above. 
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5. Results 
 
5.1. Sex differences in gut microbiota of BTBR mice 
 
5.1.1. Overall structure of gut microbiota of male and female 
BTBR mice. 
 
We analyzed sex-related profiles of gut microbiota in BTBR mice to gain 
insights into relationship between autistic behavior and dysbiosis. To this 
purpose, fecal microbiota of fully symptomatic, 12 months old, female and 
male BTBR (fBTBR and mBTBR, respectively; n=6 mice each group) and 
female and male C57 control mice of same age (fC57 and mC57, 
respectively; n=6 mice each group) was analyzed by next generation 
sequencing (NGS) technology using the Illumina Miseq system. V3–V4 
variable regions of the 16S rRNA gene were amplified and sequenced to 
characterize total bacterial population; 62,009.83 ± 33,665.39 high-quality 
sequences/sample were obtained from all 24 fecal samples, representing 
3,250 operational taxonomic units (OTUs). The results shown were obtained 
considering a depth of 32,288 sequences/sample clustered in 2,740 OTUs; 
Good’s coverage > of 99.3% for all sequences in the four groups indicated 
good sequencing depth for reliable investigation of differences in fecal 
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microbiota between BTBR and control mice. Among the 2,740 OTUs 
detected across any of the samples, 245 OTUs discriminated between 
fBTBR and fC57 mice, while 167 discriminated between mBTBR and mC57 
mice. Discriminant OTUs were identified using two complementary 
analyses, LEfSe algorithm and Metastats comparison. 
We evaluated ecological features of fecal bacterial communities in fBTBR 
and mBTBR compared to those of control groups. No significant differences 
in species richness (number of OTUs) and degree of homogeneity 
abundance of the species (Shannon index) were observed between groups 
(data not shown), while strong differences in phylogenetic assortment were 
detected comparing fBTBR and mBTBR with their respective controls (Fig. 
5.1.1). Phylogenetic distances among samples were assessed by means of 
Unweighted Unifrac distance metrics, a qualitative phylogenetic measure 
that considers the presence/absence of a taxon. ANOSIM R statistic revealed 
a difference in gut bacterial assortment between BTBR of both sexes and 
their respective controls, with fBTBR vs fC57 displaying a higher R value 
compared to mBTBR vs mC57. This effect was evident in the PCoA plot, 
where fBTBR samples clustered to the extreme right of the plot, while 
mBTBR samples were positioned midway between fBTBR and control 
samples of both sexes (Fig. 5.5.1A, left plot). 
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Sequencing data revealed that 89.1% of total reads were taxonomically 
classified in Bacteroidetes and Firmicutes phyla, and the majority of 
discriminatory OTUs, both in females and males, were classified in these 
phyla. The impact of these taxa was evident when the Unweighted Unifrac 
analysis was repeated after negative filtering of these phyla from total 
sequences. After subtraction, ANOSIM analysis on remaining OTUs 
revealed a weaker grouping level among samples (Fig. 5.1.1A, right plot), 
indicating that Bacteroidetes and Firmicutes were the principal contributors 
to the BTBR and C57 gut microbiota differences both in female and male 
mice. 
 
5.1.2. Gut microbiota profiling of BTBR female and male mice 
 
Over the total of 9 identified bacterial phyla, comparison of mean 
abundances (by nonparametric Kruskal-Wallis test) of primary 
(Bacteroidetes, Firmicutes) and most of the less abundant phyla showed no 
significant differences between fBTBR and mBTBR compared to their 
respective controls (Fig. 5.1.1B). However, we found only a significant 
difference of Proteobacteria amount, with an increase in fBTBR rather than 
fC57 (relative abundance 13.2% ± 2.6% and 4.7% ± 1.2%, respectively), and 
for TM7 phylum which was found significantly less abundant in fBTBR than 
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fC57 (relative abundance of 0.1% ± 0.04% in fBTBR and 0.3% ± 0.05% in 
fC57). No significant differences were found for all phyla identified in 
mBTBR compared to mC57 (Fig. 5.1.1B). 
 
5.1.3. Key phylotypes driving gut microbiota profiles of male 
and female BTBR mice 
 
In order to identify gut microbiota key phylotypes responsible for 
differences between fBTBR and mBTBR compared to controls we applied 
LEfSe algorithm. 17/30 key genera were found within Bacteroidetes and 
Firmicutes phyla, mainly within Bacteroidales and Clostridiales orders, even 
though the comparison of the relative abundances of these phyla did not 
show significant differences (Fig. 5.1.1B). This result confirmed that 
Bacteroidetes and Firmicutes taxa reassortment mainly marks the 
differences in the gut microbiota between BTBR and C57 mice in both sexes 
accordingly to ANOSIM results on Unweighted Unifrac analysis (Fig. 
5.1.1A). Among key genera with relative abundance > 0.1%, Bacteroides 
and Parabacteroides (order Bacteroidales) were significantly more 
abundant in BTBR female and male compared to control mice (Table 5.1.1). 
Conversely, the genus Dehalobacterium (order Clostridiales) was 
significantly less abundant in BTBR mice of both sexes compared to 
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controls (Table 5.1.1). Notably, the identified differences in relative 
abundance of Bacteroides and Parabacteroides were more pronounced in 
fBTBR as indicated by fold change (Table 5.1.1). Among the other key 
genera, Prevotella, Coprobacillus, Sutterella, Akkermansia (muciniphila) 
and unclassified members of Desulfovibrionaceae and Enterobacteriaceae 
significantly increased, while Oscillospira and members of Rikenellaceae 
and TM7 (AF12 and U. F16, respectively) significantly decreased in fBTBR, 
possibly driving a female-specific microbial signature in BTBR mice. Key 
genera specifically altered in mBTBR were Lactobacillus, Ruminococcus, 
Desulfovibrio and unclassified member of Helicobacteriaceae (Table 5.1.1). 
Genus Oscillospira accounted for 13.7% in fC57 and was found 
significantly reduced to 5.4% in fBTBR. 
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Figure 5.1.1. Female and male BTBR mice exhibit an altered gut microbial 
composition. (A) Unweighted UniFrac-based 3D PCoA plot constructed on all OTUs 
(32,288 reads per sample, left) or all OTUs without Bacteroidetes and Firmicutes reads (850 
reads per sample, right) of fecal community of BTBR and C57 mice of both sexes. Analysis 
of similarity (ANOSIM) with 999 permutations was used to detect the statistical significant 
differences in microbial community composition between fBTBR and mBTBR compared 
to their controls (fC57 and mC57); on the top of plots are reported both R statistics and p 
values. (B) Relative abundance of all identified OTUs classified at phylum level. Mean 
values ± SEM are plotted (n=6/group). Significant differences are indicated by *p<0.05 and 
**p<0.01 for comparison of fBTBR vs. fC57 and mBTBR vs. mC57. Abbreviations: 
fBTBR (BTBR female mice); mBTBR (BTBR male mice); fC57 (C57 female mice); mC57 
(C57 male mice). 
 
82 
 
 
Table 5.1.1. Relative abundance of key genera discriminating female and male BTBR 
from their sex-matched control mice. Key genera were identified applying the 
metagenomic biomarker discovery approach of LEfSe and only genera with an LDA 
significant threshold > 2 and relative abundance > 0.1% in at least one group of mice, are 
shown. Fold change was expressed as ratio between the value of mean relative abundance 
of each genus in fBTBR and mBTBR groups and the value found in the sex-matched 
controls. Data are shown as average and SEM (n = 6/group). Abbreviations: fBTBR (BTBR 
female mice); mBTBR (BTBR male mice); fC57 (C57 female mice); mC57 (C57 male 
mice). 
 
 
5.1.4. Alteration in behavioral phenotype, intestinal integrity, 
and immunity in female and male BTBR mice: 
correlation with gut microbiota modifications  
 
After a deep description of BTBR gut microbiota composition, the next step 
was to investigate the possible correlation between the levels of specific 
bacterial taxa and peculiar pathological traits dysregulated in ASD patients 
such as behavioral abnormalities, gut permeability and immune 
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abnormalities (131, 218). For all behavioral tests, both female and male 
BTBR mice showed deficits compared to controls, however a significant 
sex-related alteration was observed with fBTBR displaying higher self-
grooming scores (Fig. 5.1.2A–C). Alteration of gut permeability, as 
evidenced by increased FITC-dextran translocation across the intestinal 
epithelium into blood, was observed both in female and male BTBR mice 
(Fig. 5.1.3A). Consistently, a significant reduction of transcription of 
occludin and zonuline-1 was detected in colon of mBTBR mice and a similar 
trend was observed in fBTBR (Fig. 5.1.3B). In addition, expression of a 
subset of cytokines (TNF-a, IL-6 and IL-10) and CD11c integrin were 
determined in colon tissue of male and female BTBR and C57 mice (Fig. 
5.1.3C). Increased expression of TNF-a was observed in BTBR mice of 
both sexes. Significant increase of IL-6 and CD11c was observed in mBTBR 
compared to both sex-matched controls and fBTBR. Furthermore, 
histological evaluation of colon tissues showed tissue damage and evident 
inflammatory cells infiltration in both mBTBR and fBTBR (Fig. 5.1.4). 
Pearson correlation was applied to correlate the abundance of key genera, 
that discriminated fBTBR and mBTBR from sex-matched controls, with 
behavioral tests, colon mRNA expression of occludin, zonuline-1 and 
immune-markers (Fig. 5.1.5). In particular, increase of Parabacteroides and 
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Sutterella, together with decrease of Dehalobacterium, Oscillospira and 
unclassified member of TM7 were strongly associated to altered behavior 
and TNF-a expression in fBTBR. Unclassified members of 
Helicobacteriaceae associated to autistic phenotype and low IL-10 
expression in mBTBR. Finally, in mBTBR mice lower levels of 
Dehalobacterium, Ruminococcus and Desulfovibrio were associated to 
increased gut permeability (Fig. 5.1.5). 
 
Figure 5.1.2. Analysis of social interaction, stereotyped and repetitive behavior in 
female and male BTBR mice. (A) Three-chamber social interaction test showing time 
spent in each chamber by BTBR and C57 mice of both sexes (n=12/group; p = 0.7424 for 
chamber, p=0.0077 for strain, p=0.7761 for sex, p<0.0001 for chamber x strain and p = 
0.1671 for chamber x strain x sex, by three-way ANOVA). (B) Number of buried marble 
by BTBR and C57 mice of both sexes after 30 min testing session (n=12/group; p<0.0001 
for strain, p=0.1322 for sex and p=0.2689 for strain x sex, by two-way ANOVA). (C) 
Seconds spent in repetitive grooming measured for BTBR and C57 mice of both sexes 
during 10 min test session (n=12/group; p<0.0001 for strain, p=0.0372 for sex, and 
p=0.0269 for strain x sex, by two-way ANOVA). Significant differences are indicated by 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 using Bonferroni post-hoc tests 
following three-way ANOVA with chamber, strain and sex as factors (A) or two-way 
ANOVA with strain and sex as factors (B and C). Abbreviations: fBTBR (BTBR female 
mice); mBTBR (BTBR male mice); fC57 (C57 female mice); mC57 (C57 male mice). Data 
are shown as mean values ± SEM. 
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Figure 5.1.3. Analysis of intestinal integrity and inflammation levels in female and 
male BTBR mice. (A) Intestinal epithelial permeability to fluorescein isothiocyanate 
(FITC)-dextran 4 kDa of BTBR and C57 mice of both sexes. Data are represented as plasma 
concentration of FITC dextran (nM) (n=5/group; p=0.0002 for strain, p=0.0469 for sex and 
p=0.8187 for strain x sex, by two-way ANOVA). (B) Colon occludin (Ocln) and zonuline-
1 (Tjp1), gene expression normalized to GAPDH gene in BTBR and C57 mice of both 
sexes. Data were normalized to mC57 control (n=6/group; Ocln: p=0.0067 for strain, 
p=0.9105 for sex and p=0.1623 for strain x sex; Tjp1: p=0.0004 for strain, p=0.6202 for sex 
and p=0.9105 for strain x sex, by two-way ANOVA). (C) Colon mRNA levels of 
inflammatory markers (CD11c, IL-10, IL-6 and TNF-a) normalized to GAPDH in BTBR 
and C57 mice of both sexes. Data for each gene were normalized to mC57 controls 
(n=6/group; CD11c: p=0.0529 for strain, p=0.0018 for sex and p=0.019 for strain x sex; IL-
10: p=0.0041 for strain, p=0.7827 for sex and p=0.9739 for strain x sex; IL-6: p=0.0106 for 
strain, p=0.0107 for sex and p=0.002 for strain x sex; TNF-a: p<0.0001 for strain, p=0.2196 
for sex and p=0.0354 for strain x sex, by two-way ANOVA). In bar charts, all data are 
expressed as mean values ± SEM; significant differences are indicated by *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001; near-significant differences are also reported 
(Bonferroni post-hoc tests following two-way ANOVA with strain and sex as factors). 
Abbreviations: fBTBR (BTBR female mice); mBTBR (BTBR male mice); fC57 (C57 
female mice); mC57 (C57 male mice). 
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Figure 5.1.4. Histological evaluation of colon inflammatory cell infiltration in female 
and male BTBR mice. Representative hematoxylin and eosin–stained sections from colon 
tissues of mice. (a) Colon tissue from mC57 mice showing absence of inflammatory cells. 
(b) Colon tissue of mBTBR group showing leukocyte infiltration in the mucosa and 
submucosa. (c) Colon tissue of fC57 group, showing absence of inflammatory cells. (d) 
Colon tissue from fBTBR group showing moderate leukocyte infiltration in the mucosa. 
Original magnification 10x. Histological evaluation of inflammatory cells infiltration was 
scored along the entire colon length, inspecting the colon mucosa, submucosa and 
transmural areas considering the following parameters: leukocyte density (mC57 = 0.33 ± 
0.58, mBTBR = 2 ± 1, fC57 = 0, fBTBR = 2.67 ± 0.58) and expansion of leukocyte 
infiltration (mC57 = 0.33 ± 0.58, mBTBR = 1.33 ± 0.58, fC57 = 0, fBTBR = 1.67 ± 0.58). 
The histologic scoring system is reported in Material and Methods section. Data reported 
as mean ± SD, n=3/group. 
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Figure 5.1.5. Correlogram showing the Pearson’s correlation between key genera and 
behavioral scores, gut integrity and immune-markers in BTBR and C57 mice of both 
sexes. Blue circles designate a positive correlation while red ones designate a negative 
correlation. With X are barred no significant results according to the significance level of 
0.05. 
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5.2. PEA counteracts autistic-like phenotype in 
BTBR mice 
 
5.2.1. PEA reduced repetitive behaviour and increased sociability 
in BTBR mice 
 
The number of buried marbles and the time spent in home cage self-
grooming represent indexes of the repetitive/perseverative phenotype, 
typical of autistic-like behaviour. We observed that BTBR mice buried a 
greater number of marbles (Fig. 5.2.1A) and displayed higher self-grooming 
scores (Fig. 5.2.1B) compared to control mice. PEA at low dose (10 mg/kg) 
induced a slight improvement in the repetitive behaviour, whereas at the 
highest dose (30 mg/kg) this drug significantly decreased stereotyped 
behaviours in both marble buried (Fig. 5.2.1A) and self-grooming scores 
(Fig. 5.2.1B). 
To assess PPAR-α involvement in PEA effect, BTBR mice were treated with 
the PPAR-α antagonist GW6471 before PEA administration. The highest 
dose of PEA failed in exerting its effect on both repetitive behaviours when 
it was associated to PPAR-α antagonist (Fig. 5.2.1C-D). GW alone had no 
effect on BTBR mice in both behavioural paradigms. Consistently, PEA 
treatment did not modify the autistic-like traits showed by PPAR-α null mice 
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in both behavioural tests (Fig. 5.2.1E-F), indicating the essential 
involvement of PPAR-α activation. 
 
Figure 5.2.1. Effect of PEA on repetitive stereotyped autist-like behaviour of BTBR 
mice and involvement of PPAR-α. (A-B) Number of buried marbles and self-grooming 
time of control B6 and BTBR mice following i.p. daily administration of Vehicle, PEA (10–
30 mg/kg) for 10 days (n=10 each group). (C-D) Number of buried marbles and self-
grooming time of control B6 and BTBR mice following daily GW 6471 (GW, 1 mg/kg i.p.) 
treatment alone or 1 hr before PEA (30 mg/kg) for 10 days (n=10 each group). (E-F) 
Number of buried marbles and self-grooming time of WT (n=9) and PPAR-α null mice 
(KO) daily i.p. treated with Vehicle (n=10) or PEA 30 mg/kg (n=10) for 10 days. All data 
are presented as means ± S.E.M. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
The following step was to investigate the possible effect of PEA on social 
interaction of BTBR mice, using the three-chambered social test. BTBR 
mice failed to display significant sociability both on time in the zone (Fig. 
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5.2.2A) and on time in social sniffing (Fig. 5.2.2B) during the second phase 
of the automated three-chambered social approach task compared to control 
mice. PEA treatment improved sociability of BTBR mice: at the dose of 10 
mg/kg, mice spent equal time in the zone and in sniffing the novel mouse 
and the novel object, while, at 30 mg/kg, they significantly spent more time 
in the mouse chamber and in sniffing the mouse compared to the object (Fig. 
5.2.2A-B).  
Then, PPAR-α involvement was assess in social behaviour of BTBR mice. 
Results showed that PEA failed to improve sociability both in time in the 
zone and in sniffing time of BTBR mice, when pre-treated with GW (Fig. 
5.2.2C). These findings were confirmed by reduced sniffing for mouse in 
pre-treated mice with GW than PEA group (Fig. 5.2.2D). The treatment with 
GW alone had no effect on BTBR mice. PEA treated PPAR-α null mice 
showed equal time spent in the mouse zone and in sniffing time with the 
mouse and the object (Fig. 5.2.2E-F). Vehicle treated PPAR-α null mice 
showed a not significant preference for the object side (Fig. 5.2.2E-F). 
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Figure 5.2.2. Effect of PEA on social behaviour of BTBR mice and involvement of 
PPAR-α. (A) Time in the zone (B) and sniffing time during the second social preference 
phase of 3-chambered social test of control B6 and BTBR mice following i.p. daily 
administration of Vehicle, PEA (10–30 mg/kg) for 10 days (n=10 each group). (C) Time in 
the zone (D) and sniffing time during the sociability phase of 3-chambered social test of 
control B6 and BTBR mice following daily GW 6471 (GW, 1 mg/kg i.p.) treatment alone 
or 1 hr before PEA (30 mg/kg) for 10 days (n=10 each group). (E) Time in the zone (F) and 
sniffing time during the sociability phase of 3-chambered social test of WT (n=9) and 
PPAR-α null mice (KO) daily i.p. treated with Vehicle (n=10) or PEA 30 mg/kg (n=10) for 
10 days. All data are presented as means ± S.E.M. *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. 
 
During the last phase of the test, we analysed the time spent in area and the 
time spent in sniffing familiar or new mouse (Figure 5.2.3). All BTBR and 
B6 groups spent more time in the chamber with the novel mouse than the 
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familiar mouse, as well as in sniffing time, indicating no behavioural 
impairment in this phase of the test in vehicle- or treated BTBR mice. 
Instead, vehicle- or PEA-treated PPAR-α null mice showed a significant 
preference for the familiar mouse. 
 
 
Figure 5.2.3. Effect of all treatments on social novelty behaviour in mice. Social novelty 
was measured as time spent with the new mouse versus the familiar mouse during the last 
phase of the 3-chambered social test. (A, C) All groups significantly prefer to spent time in 
the new mouse side compared to the familiar mouse side as well as sniffing time (B, D). 
(E) KO mice spent more time in the zone with familiar mouse and in (F) sniffing the familiar 
mouse than the new mouse. Here, PEA at the dose of 30 mg/kg did not change mouse 
behaviour. Results are showed as mean ± S.E.M., n= 10 for each group; * p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
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A single PEA administration (30 mg/kg i.p.) in BTBR mice was also tested, 
revealing no effect after 1 hour on all behavioural tests (Figure 5.2.4A-F) 
demonstrating no early fast effect of PEA. 
 
 
Figure 5.2.4. Effect of a single i.p. administration of PEA 30mg/kg in BTBR mice. (A) 
No significant difference in number of buried marbles and (B) self-grooming time was 
found between PEA 30 mg/kg and vehicle treated BTBR mice. (C) Time spent in the zone 
and (D) sniffing time between the chamber containing the mouse and the chamber 
containing the object showed no behavioural difference between PEA and vehicle treated 
BTBR mice; both groups significantly prefer to spend time in the object side compared to 
the mouse side. (E) Time spent in the zone and (F) sniffing time between the chamber 
containing the familiar mouse and the new mouse showed no behavioural difference 
between PEA and vehicle-treated BTBR mice. Here, both treated and untreated BTBR mice 
significantly prefer to spend time in the new mouse side compared to the familiar mouse 
side. Results are showed as mean ± S.E.M.; n=10 for each group. * p<0.05; **p<0.01; 
***p<0.001. 
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Moreover, all behavioural skills were not affected by PEA in control mice, 
indicating that this drug had no behavioural effects per se (Figure 5.2.5A-
C). 
 
 
Figure 5.2.5. Effect of daily i.p. administration of PEA 10 mg/kg and 30 mg/kg for 10 
days in B6 control mice. (A) No significant difference in number of buried marbles and 
(B) self-grooming time was found in control B6 mice treated with PEA or vehicle. (C) 
Social novelty was measured as time spent in the new mouse side versus the familiar mouse 
side during the last phase of 3-chambered social test. Here, both PEA-treated and vehicle-
treated B6 mice significantly prefer to spend time in the new mouse side compared to the 
familiar mouse side. Results are showed as mean ± S.E.M.; n=9 for each group. **p<0.01; 
***p<0.001; ****p<0.0001. 
 
In order to exclude the induction of anxiety and/or locomotor deficits by 
treatments, we tested all mice in open field and EPM test, revealing no 
difference due to treatments, but only an overall difference between strains 
(Figure 5.2.6A-H). 
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Figure 5.2.6. Effect of all treatments on locomotor activity and anxiety behaviour. 
BTBR and PPAR-α KO mice treated with PEA (30 m/kg), GW6471 (1 mg/kg) alone or in 
combination with PEA, compared to vehicle treated control B6 mice, were subject to (A-
D) open field and (E-H) elevated plus maze test. (A, B) Both BTBR and vehicle PPAR-α 
KO mice exhibit an increased locomotor activity compared to B6 mice, during 10 minutes 
of freely movement in the open field test. (C) BTBR mice spent the same percentage of 
time in the centre of the arena compared to B6 mice. (D) PPAR-α KO mice significantly 
spent less percentage of time in the centre of the arena compared to control mice. No 
significant differences were found in the number of entries in open arms of (E, F) BTBR 
mice and PPAR-α KO mice compared to B6 mice and in the number of total arms entries 
(G, H) of BTBR and PPAR-α KO mice compared to B6 mice during the EPM test. No 
significant effect of all drug treatments was detected on both tests. Results are shown as 
mean ± S.E.M. *p<0.05; **p<0.01. 
 
5.2.2. PEA improves BDNF/TrkB system, increasing 
hippocampal PPAR-a expression 
 
As well known by literature, ASD is characterized by an impairment of 
BDNF/TrkB system signalling and its downstream CREB activation (219). 
Here, BTBR mice showed lower level of hippocampal BDNF and a partial 
reduction of TrkB in both mRNA and protein expression than B6 control 
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mice (Fig. 5.2.7A-D). PEA treatment (30 mg/kg) restored both BDNF (Fig. 
5.2.7A-B) and TrkB expression (Fig. 5.2.7C-D) in BTBR mice. 
Furthermore, although CREB mRNA level did not significant change by 
PEA treatment (30 mg/kg) (Fig. 5.2.7E) in BTBR mice, the phosphorylation 
of protein CREB was significantly increased by PEA administration (Fig. 
5.2.7F). 
To strengthen PPAR-α role in autism, we subsequently evaluated PPAR-α 
expression in the hippocampus. BTBR mice displayed a significant 
reduction in PPAR-α mRNA and protein expression, that were significantly 
reconstituted by PEA treatment (30 mg/kg) at both mRNA and protein level 
(Fig. 5.2.7G-H). 
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Figure 5.2.7. PEA effect on hippocampal gene transcription and protein expression. 
RT-PCR detection of (A) BDNF, (C) TrkB, (E) CREB, and (G) PPARα and western blot 
analysis of (B) BDNF, (D) TrkB, (F) p-CREB and CREB, and (H) PPARα in the 
hippocampus were performed from B6 and BTBR mice treated with vehicle or PEA 30 
mg/kg (n=7–11 per group) for 10 days. Representative immunoblots from 2–3 animals each 
group following the above treatments are shown. Signals from each animal were quantified 
and peptide expression was shown as a ratio of housekeeping gene β-Actin (Actin) and with 
total CREB. Results are expressed as mean ± S.E.M. *p<0.05; **p<0.01; ***p<0.001; 
****p<0.001. 
 
5.2.3. PEA treatment improves hippocampal mitochondrial 
function and reduces oxidative stress 
 
Mitochondrial state 3 respiration using succinate as substrate was decreased 
in BTBR mice compared with B6. Repeated treatments of PEA restored 
mitochondrial respiration (Fig. 5.2.8A left side), whereas no variation was 
observed in mitochondrial state 4 respiration (Fig. 5.2.8A right side). No 
variation was found in oligomycin state 4 respiration (Fig. 5.2.8B left side), 
while a significant decrease was found in maximal FCCP-stimulated 
respiration in PEA treated mice compared BTBR mice (Fig. 5.2.8B right 
side). As a consequence, hippocampal mitochondrial energetic efficiency 
(q), assessed as degree of coupling, was significantly lower in PEA treated 
mice compared to BTBR mice (Fig. 5.2.8C). 
ROS production was significantly increased in hippocampus from BTBR 
mice and blunted by PEA treatment (Fig. 5.2.8D); consistently, BTBR mice 
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showed a significant lower SOD activity, which was restored by PEA (Fig. 
5.2.8E). 
 
 
Figure 5.2.8. Effect of PEA on mitochondrial and oxidative stress. (A) Mitochondrial 
respiration in the presence of succinate as substrate, (B) oxygen consumption in the 
presence of oligomycin (left side), or FCCP (right side) and (C) degree of coupling values 
calculated from oxygen consumption in the presence of oligomycin and FCCP in the 
hippocampus from B6 and BTBR mice following daily i.p. administration of vehicle or 
PEA 30 mg/kg for 10 days (n=12 per group). (D) ROS production in the hippocampus from 
mice of all groups (n=12 per group). (E) SOD activity in the hippocampus (n=5) All data 
are presented as mean ± S.E.M. *p<0.05; **p<0.01; ***p<0.001. 
 
5.2.4. PEA reduces central, systemic and intestinal 
inflammation 
 
Neuroinflammation represents one of the crucial basis of ASD pathogenesis 
and progression. Indeed, pro-inflammatory cytokines are correlated with 
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impaired sociability and aberrant behaviour linked to ASD in both humans 
and mice (220, 221). BTBR mice showed increased level of TNF-α, IL-1β, 
and IL-6 in the hippocampus compared to B6 mice and PEA was able to 
reduce them (Fig. 5.2.9A-C). Similarly, we demonstrated the same cytokine 
profile at serum and colonic level (Fig. 5.2.9D-I). These results revealed 
both peripheral and central effects of PEA in autistic mice, opening a new 
scenario on the mechanism of action of PEA. 
 
 
Figure 5.2.9. PEA modulation of central and peripheral inflammatory cytokines. 
Changes in TNF-α, IL-1β, and IL-6 mRNA levels in (A-C) hippocampus, (D-F) colon, and 
(G-I) serum of B6 or BTBR mice following daily i.p. administration of vehicle or PEA 30 
100 
 
mg/kg for 10 days (n=6 per group). Results are shown as mean ± S.E.M. *p<0.05; **p<0.01; 
***p<0.001. 
 
5.2.5. PEA effects on gut permeability and microbiota 
 
BTBR mice are characterized by a compromised epithelial barrier integrity: 
a significant increase in gut permeability was shown in vivo in BTBR mice 
evaluating the plasmatic levels of FITC-labelled dextran 24 h after its oral 
administration (Fig. 5.2.10A). Molecular analysis showed PEA-induced 
improvement of epithelial barrier integrity of BTBR mice, increasing of Tjp1 
and Ocln mRNA transcripts in colonic tissues found significantly reduced in 
BTBR mice compared to B6 control mice (Fig. 5.2.10 B-C). 
 
 
Figure 5.2.10. PEA effect on intestinal permeability. (A) In vivo permeability was 
detected by plasmatic levels of FITC-labelled dextran from B6 or BTBR mice following 
daily i.p. administration of vehicle or PEA 30 mg/kg for 10 days (n=6 per group). Changes 
in mRNA expression of zonuline-1 (B) and occludin (C) in colon tissue from B6 or BTBR 
mice following daily i.p. administration of vehicle or PEA 30 mg/kg for 10 days (n=6 per 
group). 
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Faecal microbiota composition was analysed by next-generation sequencing 
method to evaluate the effect of PEA administration on gut microbial 
communities of BTBR mice with respect to similar ages of cases of 
untreated BTBR and B6 control mice. Alpha diversity analyses did not show 
significant alteration in bacterial species richness and diversity within 
groups. On the contrary, measuring phylogenetic distances by beta diversity 
analyses, we found significant differences in microbial species assortment 
(unweighted beta diversity) among groups (see Table 5.2.1). Interestingly, 
R statistic ANOSIM, computed on phylogenetic distances among samples, 
revealed that upon PEA treatment the overall microbial community of 
BTBR mice was restructured and resulted significantly different from that 
of untreated BTBR mice (Table 5.2.1). 
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Table 5.2.1. Significant differences in microbial species assortment among groups. 
Alpha diversity indexes reported as mean ± SD (Upper panel). R statistics and p-values of 
analysis of similarity (ANOSIM) with 999 permutations computed on unweighted and 
weighted UniFrac distances between groups (Lower panel). 
 
PEA treatment strongly impacted on levels of definite identified phyla. 
Among the 9 phyla detected, Bacteroidetes and Firmicutes were the most 
abundant and primarily affected by PEA treatment (Fig. 5.2.11A); 
Firmicutes/Bacteroidetes ratio was considerably higher in BTBR mice 
treated with PEA due to significant increase in Firmicutes and decrease in 
Bacteroidetes (Fig. 5.2.11A). At genus level, the increase of 
Firmicutes/Bacteroidetes ratio upon PEA administration was mainly a 
Alpha diversity 
 C57 BTBR BTBR PEA 
Observed 
species 430.9 ± 51.1 425.3 ± 46.7 505.25 ± 38.5 
Shannon 6.2 ± 0.3 6.1 ± 0.4 6.4 ± 0.05 
Good’s 
coverage 0.987 ± 0.001 0.986 ± 0.001 0.984 ± 0.001 
Beta diversity 
 C57 vs BTBR BTBR vs BTBR PEA C57 vs BTBR PEA 
Unweighted 
UniFrac 
distances 
R= 0.937 (p < 0.01) R= 0.0522 (p < 0.01) R= 0.917 (p < 0.01) 
Weighted 
UniFrac 
distances 
R= 0.293 (p < 0.05) R= 0.0513 (p = 0.01) R= 0.398 (p < 0.01) 
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consequence of diminution of Bacteroides, U. g. of Rikenellaceae, U.g. of 
S24-7 (phylum Bacteroidetes) and increase of U.g. of Clostridiales (phylum 
Firmicutes) (Fig. 5.2.11B). Thus, PEA treatment establishes a new 
microbiota profile, marking differences with microbiota composition found 
in untreated BTBR mice and recovering similarities for some aspects with 
microbial assortment of B6 control mice. 
 
 
Figure 5.2.11. PEA effect on faecal microbiota composition. (A) Phylum level 
composition of fecal microbiota from B6 and BTBR mice following daily i.p. 
administration of vehicle or PEA 30 mg/kg for 10 days (n=6 per group). (B) Bacterial genera 
belonging to Bacteroidetes and Firmicutes phyla found to be significantly different among 
groups (n=6 per group). Results are showed as mean ± S.E.M. *p<0.05; **p<0.01; 
***p<0.001 ****p<0.0001. 
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5.3. PEA limits HFD-induced depression   
 
5.3.1. PEA lessens depressive-like behaviour and memory 
deficit 
 
In forced swimming test (Fig. 5.3.1A) and tail suspension test (Fig. 5.3.1B), 
HFD caused a significant increase in immobility time, related to depressive-
like behaviour of mice. After 7 weeks of treatment, PEA induced an increase 
in HFD mice responsiveness and effort to escape than untreated HFD group. 
Furthermore, during the novel object recognition test, we have evaluated the 
time (Fig. 5.3.1C) and the number of entries (Fig. 5.3.1D) of mice in the 
areas, in which the new and the old object were placed. While HFD induced 
an impairment in the recognition of old object, PEA was able to restore the 
curiosity of mice. The open field test highlighted that PEA partially 
stimulated the movement of HFD mice, reduced by HFD intake (Fig. 
5.3.1E-H). 
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Figure 5.3.1. PEA effects on depressive-like behavior, memory recognition and 
locomotor activity. STD, HFD and PEA-treated HFD mice (n=10 each group) were 
subjected to forced swimming test (A), tail suspension test (B), novel object recognition test 
(C-D) and open field test (E-H). (A-B) HFD group mice showed an increased immobility 
time in both tests for depressive-like behaviour that was significantly improved by PEA 
treatment. During NORT, PEA stimulated the curiosity on new object similar to that of STD 
group, both in the (C) time and the (D) number of entries. (E-H) The locomotor activity of 
HFD and HFD+PEA was reduced compared to STD group, even if the treatment with PEA 
induced a trend of improvement. Results are shown as mean ± S.E.M. *p<0.05, **p<0.01, 
***p<0.001 vs STD and #p<0.05 vs HFD. 
 
5.3.2. PEA improves serum metabolic and inflammatory 
parameters 
 
After 19 weeks of HFD feeding, serum triglycerides and ALT (Fig. 5.3.2A-
B) were altered compared to STD group and PEA significantly reduced these 
parameters. Similarly, the hormonal profile drastically compromised by high 
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fat feeding was improved by PEA, as shown by leptin and adiponectin serum 
levels (Fig. 5.3.2C-D). PEA carried out its anti-inflammatory activity 
reducing serum levels of inflammatory mediators (TNF-a, IL-1b and MCP-
1) (Fig. 5.3.2E-G), elevated by HFD. 
 
 
Figure 5.3.2. PEA restored serum metabolic parameters and decreased pro-
inflammatory mediators. HFD feeding compromised serum metabolic profile, altering (A) 
triglycerides, (B) ALT, (C) leptin and (D) adiponectin levels. PEA was able to improve 
these parameters. In addition, this molecule decreased serum levels of pro-inflammatory 
mediators, such as (E) TNF-α, (F) IL-1β and (G) MCP-1, significantly increased in HFD 
mice. Results are shown as mean ± S.E.M from n = 6 animals/group. ****p<0.0001 vs 
STD; ##p<0.01, ###p<0.001 ####p<0.0001 vs HFD. 
 
5.3.3. Activation of POMC neurons by PEA in ARC  
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To evaluate the activation of anorexigenic POMC neurons in ARC of 
hypothalamus, we performed the staining of c-fos in POMC in both all three 
experimental groups (Fig. 5.3.3A). As shown by Fig. 5.3.3B, the number of 
activated POMC neurons in HFD mice was significantly reduced compared 
to STD group and increased after PEA treatment. Furthermore, we also 
demonstrated PEA capability in increasing the transcription of BDNF in 
hypothalamus, altered by HFD (Fig. 5.3.3C). 
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Figure 5.3.3. PEA stimulated POMC neurons in ARC and neurogenesis in 
hypothalamus. As shown by immunostaining of (A) c-fos in POMC neurons in ARC, PEA 
was able to increase (B) the number of activated POMC neurons, significantly diminished 
by HFD. Moreover, PEA also increased the transcription of (C) BDNF in hypothalamus. 
Results are showed as mean ± S.E.M from n=6 animals/group for immunostaining and n=10 
animals/group for real time PCR. *p<0.05 vs STD; #p<0.05, ###p<0.001 vs HFD. 
 
5.3.4. PEA reduces neuro-inflammation in hypothalamus 
IBA-1, a protein generally expressed by microglia, resulted up-regulated 
during inflammation. Indeed, HFD caused an increase of IBA-1 cells in 
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ARC of hypothalamus and PEA was able to reduce this parameter, 
indicating PEA protective effect on microgliosis (Fig. 5.3.4A-B). 
Furthermore, this acylethanolamide also reduced NF-κB and IL-1b 
transcription in hypothalamus, altered by HFD (Fig. 5.3.4C-D). 
These experiments were performed in the laboratory of Prof. Sabrina Diano 
at Yale University, Department of Obstetrics, Gynecology & Reproductive 
Sciences, located in New Haven (Connecticut, USA), from January 2017 to 
January 2018. 
 
Figure 5.3.4. PEA reduces microgliosis and inflammation in hypothalamus. As shown 
by immunostaining of (A) IBA-1 in ARC of hypothalamus, PEA was able to decrease the 
number of activated microglia, markedly altered by HFD. Moreover, PEA reduced the 
transcription of pro-inflammatory mediators, such as (B) NF-kB and (C) IL-1b in 
hypothalamus. Results are shown as mean ± S.E.M from n=6 animals/group for 
immunostaining and n=10 animals/group for real time PCR. *p<0.05, ***p<0.001 and 
****p<0.0001 vs STD; #p<0.05 vs HFD. 
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5.3.5. PEA improves BDNF/CREB system and reduces HFD-
induced inflammation in hippocampus 
The hippocampal dysfunction of BDNF/CREB system as pathogenic 
mechanism of MDD is well known (222). In our experimental condition, 19 
week-HFD caused a significant reduction of the phosphorylation of CREB 
and protein expression of BDNF, improved by PEA treatment (Fig. 5.3.5 A-
B). These data were confirmed by the improvement of PEA in mRNA levels 
of BDNF and TrkB (Fig. 5.3.5C-D). Furthermore, PEA carried out its anti-
inflammatory activity reducing the mRNA levels of IL-1b and TNF-a, 
significantly increased by HFD (Fig. 5.3.5 E-F). 
 
Figure 5.3.5. PEA restored BDNF/CREB pathway and reduced inflammation in 
hippocampus of HFD mice. In hippocampus of HFD mice there was a reduction of (A) 
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phosphorylated CREB and (B) BDNF expression. PEA was able to increase these 
parameters, as also demonstrated by mRNA levels of (C) BDNF and (D) TrkB. In addition, 
PEA reduced also inflammatory mediators, such as (E) IL-1b and (F) TNF-a, altered by 
HFD. Results are shown as mean ± S.E.M from n=10 animals/group. *p<0.05, **p<0.01 
and ****p<0.0001 vs STD; #p<0.05, ###p<0.001 and ####p<0.0001 vs HFD. 
 
5.3.6. PEA ameliorating effect on HFD-induced depression: 
possible involvement of PPAR-a  
To explore the hypothesis that PEA activity was mediated by PPAR-a, we 
evaluated the hippocampal expression of PPAR-a, at mRNA and protein 
level, its coactivator PGC1a and the downstream factor FGF21 (Fig.5.3.6). 
PEA treatment was able to increase the expression of PPAR-a, PGC1a, and 
FGF21 in the hippocampus, indicating the involvement of PPAR-a and its 
downstream pathway in PEA mechanism of action. 
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Figure 5.3.6. PPARa involvement in beneficial effects of PEA in HFD hippocampus. 
(A) protein expression and (B) mRNA level of PPARa, and the protein expression of (C) 
PGC1a and (D) FGF21 were analysed. Results are shown as mean ± S.E.M from n=10 
animals/group. *p<0.05, **p<0.01 vs STD; #p<0.05, ##p<0.01, ###p<0.001 vs HFD. 
 
5.3.7. PEA restores BBB integrity of HFD-mice hippocampus 
The tight junctions, such as occludin and zonuline-1, play a key role in 
maintaining the integrity of endothelial membrane of BBB. The membrane 
disruption, due to the reduction of these proteins at hippocampal level, is 
related to neurodegenerative disorders, such as Alzheimer’s Disease (AD) 
(223). Here, HFD caused a significant reduction of mRNA levels of occludin 
(Fig. 5.3.7A) and zonuline-1 (Fig.5.3.7B), indicating an increase of BBB 
permeability. PEA was able to restore its integrity, inducing the transcription 
of these two tight junctions (Fig. 5.3.7). 
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Figure 5.3.7. PEA induces the transcription of TJs in hippocampus of HFD mice. 
mRNA levels of (A) occludin and (B) zonuline-1 are shown. Results are shown mean ± 
S.E.M from n=10 animals/group. *p<0.05 vs STD; #p<0.05 vs HFD. 
 
 
5.3.8. PEA effects on BDNF/CREB system in prefrontal cortex 
of HFD mice 
To evaluate the possible impact of hippocampus neuroinflammation on pre-
frontal cortex, we investigated whether HFD induced also the impairment in 
prefrontal cortex of BDNF/CREB pathway. As shown in Fig. 5.3.8, 19 
week-HFD caused a partial reduction of phosphorylated CREB and a 
significant decrease of BDNF, that were restored by PEA treatment. In 
addition, this molecule was able to reduce inflammatory mediators, such as 
IL-1b (Fig. 5.3.8C) and TNF-a (Fig. 5.3.8D), significantly and partially 
altered by HFD, respectively. 
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Figure 5.3.8. PEA restored BDNF/CREB system and reduced inflammation in 
prefrontal cortex of HFD mice. In prefrontal cortex of HFD mice there was a reduction of 
(A) phosphorylated CREB and (B) BDNF expression. PEA was able to increase these 
parameters. Moreover, PEA reduced also inflammatory mediators, such as (C) IL-1b and 
(D) TNF-a, altered by HFD. Results are shown as mean ± S.E.M from n=10 animals/group. 
*p<0.05 and ****p<0.0001 vs STD; #p<0.05, ##p<0.01 and ####p<0.0001 vs HFD. 
 
5.3.9.    PEA effects on gut microbiota composition 
A total of 606,533 quality-filtered 16S rRNA gene sequences from 12 mouse 
fecal samples were available for meta-analysis (n=4/group). Of these, 
241,734 were at least 97% similar to a sequence in the GG database and 
represented 2,104 bacterial operational taxonomic units (OTUs), prior to 
random subsampling. It was necessary to randomly subsample to a level of 
7,032 sequences per sample to describe the microbiota composition that 
have been shown to be sufficient to analyse differences between sample 
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groups (Goods Coverage>96%). After this sample rarefaction procedure, the 
resulting sequences represented 1,745 OTUs taxonomically classified in 11 
phyla and 87 genera. 
The alpha and beta diversity among the three groups were measured in order 
to evaluate the bacterial diversity in terms of species richness and 
community diversity. Alpha diversity results revealed that the intestinal 
bacterial population of HFD and HFD+PEA groups exhibited a significant 
decrease of microbial diversity (Shannon index; P<0.05; Fig. 5.3.9B), 
compared with STD group. Beta diversity, representing the distances among 
samples and groups in terms of bacterial community composition, was then 
measured. Using the ANOSIM R statistic, an index based on rank 
dissimilarity, dissimilarity between groups based on unweighted and 
weighted Unifract distances was measured (Fig. 5.3.9C-D, respectively).  
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Figure 5.3.9. Comparison of fecal microbial diversity among STD, HFD and 
HFD+PEA groups. Diversity within bacterial communities is demonstrated by the number 
of observed species (A) and the Shannon Index (B). Results are presented as the mean ± 
standard deviation. *p<0.05 vs STD, by nonparametric t-test. Diversity among bacterial 
communities is displayed in the principal coordinate analysis plot, based on unweighted (C) 
and weighted (D) Unifrac distances, with the amount of variance along each axis in 
brackets. Analysis of similarity (ANOSIM) with 999 permutations was used to detect the 
statistical signicant differences in microbial community composition among groups; on the 
bottom of plots are reported both R statistics and p values. 
 
ANOSIM analysis revealed significant differences in bacterial assortment of 
HFD and HFD+PEA samples compared to STD ones both in terms of type 
and relative abundance of shared species, while no significant differences in 
bacterial assortment were identified between HFD and HFD+PEA groups. 
These results indicated the detrimental effect on gut microbiota richness and 
variety induced by HFD.  
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Sequencing analysis revealed that Bacteroidetes, Firmicutes and 
Proteobacteria were the dominant phyla of faecal microbiota in all groups 
(Fig. 5.3.10A). Among the 11 bacterial phyla identified, comparison of 
relative abundances by Kruskal Wallis test revealed significant differences 
among groups in the levels of Actinobacteria, Bacteroidetes and 
Cyanobacteria (Fig. 5.3.10B). The treatment with PEA induced a trend of 
decrease in Proteobacteria, increased by HFD feeding. 
 
Fig. 5.3.10. Faecal microbiota composition at phylum level. Mean relative abundance of 
all identified OTUs classified at phylum level (A). Mean values ± SEM of bacterial phyla 
found to be significantly different among groups (B). Significant differences are indicated 
by *p<0.05 vs STD.  
 
At the genus level, five genera belonging to Bacteroidetes phylum were 
altered in HFD mice compared to STD. Among these, unclassified genera 
of Prevotellaceae and S24-7 families were altered both in HFD and 
HFD+PEA, whereas Af12 and Prevotella were changed only in the HFD 
group and unclassified genus of Bacteroidales only in HFD+PEA group 
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(Fig. 5.3.11A). Among Proteobacteria phyla, although Sutterella, an 
unclassified genus of Desulfovibrionaceae, and of Helicobacteraceae were 
different both in HFD and HFD+PEA group, PEA was able to induce a 
partial reduction of Desulfovibrio (Fig. 5.3.11B). Moreover, a total of 13 
Firmicutes genera were changed by treatments, with a substantially decrease 
of relative abundance of an unclassified genus of Clostridiales and an 
increase of genera Lactococcus, Ruminococcus and Allobaculum. Genera 
Lactobacillus, Clostridium and an unclassified genus of Mogibacteriaceae 
were influenced specifically by HFD and restored by PEA administration. 
While unclassified genera of Clostridiaceae and Lacnospiraceae were 
different only in HFD+PEA group (Fig. 5.3.11C). 
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Figure 5.3.11. Faecal microbiota composition at genus level. Genera are grouped 
according to belonged phyla, (A) Bacteroidetes, (B) Proteobacteria and (C) Firmicutes. 
Results are shown as mean ± S.E.M from n=4 animals/group. *p<0.05 and vs STD; #p<0.05 
vs HFD. 
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6. Discussion and conclusions 
 
6.1 Gut-brain axis in ASDs: focus on PEA beneficial 
effects 
 
ASDs are multifactorial disorders, characterized by multiple converging 
mechanisms based on genetic, epigenetic and environmental risk factors, 
even if the specific molecular and cellular features keep still unclear (224). 
In ASDs, it is usual the incidence of medical comorbidities, such as seizures, 
intellectual disability, gastrointestinal disorders, metabolic impairment and 
sleep deficiency (225, 226). In particular, several studies have focused on 
the ever-increasing relationship between gut disorders and ASDs, showing 
the presence of diarrhea/constipation, abdominal pain, gastric reflux and the 
so-called leaky gut in ASDs patients (227-229). Accordingly, previous 
studies demonstrated the beneficial effects of short-term treatment with 
antibiotics and probiotics in ASDs patients (230, 231), supporting the 
possible role of gut microbiota modulation in ASDs. Mouse models of ASDs 
have often represented a support to study and understand, not only the 
mechanisms underlying ASD pathogenesis and behavior, but also the 
communication between gut microbes and CNS. During the first part of the 
PhD programme, a gender study was performed on gut microbiota 
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composition, behavioral features, such as social interaction, stereotyped and 
repetitive movement, intestinal integrity and architecture of adult male and 
female BTBR mice, one of the most used animal model of ASDs. 
From the analysis of gut microbiota, we observed that Bacteroidetes and 
Firmicutes were the principal contributors to the BTBR and C57 gut 
microbiota differences both in female and male mice. In particular, among 
the key genera belonging to Bacteroidetes phyla, Bacteroides and 
Parabacteroides were significantly more abundant in both male and female 
BTBR mice than control group. These two genera of microrganisms are 
producers of lipopolysaccharide, an endotoxin detected in serum of autistic 
patients (232). In another clinical study, high levels of Bacteroides were 
found in fecal samples of ASDs children (233). 
Interestingly, among other phyla, we demonstrated also a gender difference. 
Indeed, we found an increase of Proteobacteria and a reduction of TM7 
phylum in fBTBR compared with fC57, not recognized between mBTBR 
and mC57. Although comparison between animal model and human studies 
should be critically analyzed for great heterogenic differences, several 
families among Proteobacteria, gut commensal species with potential 
pathogenic features, were detected in gut of ASDs children (234). In 
Proteobacteria phylum, genus Sutterella, found elevated in fBTBR, was also 
detected in fecal samples of children with ASDs or gut disorders (235, 236). 
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The unbalance of gut microbiota in BTBR mice was accompanied, in both 
males and females, by an increased gut permeability and inflammation, 
related to the occurrence of marked colonic damage, underlining again the 
strong link between ASDs and gut disturbances (131). 
Beyond the description of gut microbiota profile, we also investigated 
whether there was a possible correlation between specific microorganisms 
and behavioral or peripheral pathological features. In particular, the increase 
of Parabacteroides and Sutterella amount, associated with the reduction of 
Dehalobacterium, Oscillospira, and unclassified member of TM7, were 
strongly related to autistic behavior and high colonic expression of TNF-a 
in fBTBR. This finding goes along with Onore et al. (237), whose work 
highlighted the relationship between colonic inflammation and repetitive 
grooming behavior of BTBR mice. After the characterization of the mouse 
model of ASDs, our focus moved to the evaluation of possible central and 
peripheral activities evoked by PEA in improving autistic-like traits, 
focusing on the effects on gut-brain axis. 
PPARa targeting, using PEA as PPARa agonist, represents a novel 
therapeutic approach for ASDs treatment: indeed, some recent but still 
preliminary studies highlighted the beneficial effects of PEA in autistic 
animals and patients (96, 238, 239). 
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To this purpose, during the second part of the PhD programme, the 
beneficial and dose-dependent effects of PEA on autistic-like behavior was 
investigated using a mouse model of ASDs. In particular, we assessed the 
contribution of converging mechanisms underlying PEA effect and the 
obligatory role of PPARa in its mechanism of action. 
In BTBR mice, the treatment with PEA at higher dosage improved repetitive 
behavior and sociability. These effects were not related to possible drug-
induced confounding hyper- or hypoactivity, as confirmed by OFT and EPM 
test. In addition, a single PEA administration had no positive effect, 
demonstrating the consolidation of PEA-induced mechanisms for a delayed 
effect. We directly correlated the improved social behavior to PPARa 
activation mediated by PEA, because of the loss of its activity in both 
PPARa null mice and BTBR mice pretreated with PPARa antagonist, GW. 
These findings were strengthened by the increased PPARa mRNA and 
protein expression in the hippocampus of PEA-treated BTBR mice. In two 
preclinical studies, PPARa activation prevented cognitive dysfunction (240) 
and induced hippocampal neurogenesis after cerebral ischemia (241). In 
particular, this receptor regulates the expression and functions of several 
plasticity-related molecules through the direct transcriptional control of 
CREB (64, 65). Interestingly, ASDs are characterized by an alteration of 
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BDNF/TrkB signaling pathway and a significant reduction of BDNF-
induced synaptic transmission (219, 242, 243). Here, we found lower BDNF 
level and no significant changes of TrkB expression between BTBR and 
control mice, while PEA was able to induce both mRNA and protein 
expression compared to autistic mice. The involvement of BDNF signalling 
pathway in the molecular mechanisms contributing to PEA effect, was 
confirmed by the increase in the phosphorylation of CREB, involved in 
BDNF signalling pathway (244).  
As above mentioned, the pathogenic mechanism of ASDs is multifactorial. 
Indeed, beyond the involvement of synapse development and plasticity, it 
includes other different alterations, such as mitochondrial dysfunction, 
dysregulated immune response and chronic neuroinflammation (245). 
During their energy-generating activity, mitochondria are main responsible 
for the production of free radical species. In brain, where the demand of 
mitochondrial energy is high, these waste products can trigger pathological 
conditions. Therefore, mitochondrial dysfunction may be a key feature 
common to a wide spectrum of neurological and neurodevelopmental 
diseases, including ASDs (246). Furthermore, Anitha et al. (247) had already 
observed an altered expression of electron transport chain genes in brains of 
autistic patients. Accordingly, hippocampal mitochondria in BTBR mice 
exhibited a reduced respiratory capacity, as indicated by the decrease in 
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succinate State 3 oxygen consumption, which would partially block electron 
flow within the respiratory chain and consequently increase oxidative stress. 
Moreover, the decreased SOD activity could contribute to excessive ROS 
formation in BTBR mice. Notably, PEA treatment restored mitochondrial 
function and decreased oxidative stress partially due to the increase in SOD 
activity. A concomitant decline in mitochondrial energy efficiency, as 
evidenced by the decreased degree of coupling in PEA treatment, may also 
contribute to counteract excessive ROS formation in PEA-treated BTBR 
mice. These evidences confirm that PEA rescues hippocampal functionality, 
balancing ROS production and antioxidant defences. Therefore, PEA could 
limit all those events related to excessive ROS, such as the destruction of 
cellular components including lipids, protein, and DNA, and the trigger of 
inflammation. 
In ASDs, neuroinflammation is driven by microglial cells that acquire a M1 
phenotype and induce the production of several pro-inflammatory cytokines, 
including TNF-a, IL-1b and IL-6 (248). Indeed, in both BTBR and VPA-
induced autistic mice, Cipriani et al. (249) discovered high levels of pro-
inflammatory cytokines in brain and serum samples. Furthermore, as shown 
in the first part, the inflammatory state is also mediated by the 
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gastrointestinal system, due to increased gut permeability, synthesis of 
cytokines and alteration of gut microbiota. 
Here, PEA was able to reduce cytokine production at colonic, central and 
systemic levels, and improved intestinal permeability. Therefore, it is 
conceivable to hypothesise that systemic administration of PEA could 
directly impact neuroinflammation, being able to cross BBB, but also 
indirectly reduce peripheral inflammatory input to the brain, through its anti-
inflammatory properties in periphery. Therefore, our hypothesis is that PEA 
would reduce the trafficking of inappropriate gut-derived detrimental factors 
into the portal circulation and the crossing through a permissive BBB, 
leading to a reduction in systemic and ultimately central inflammation. 
Finally, PEA peripheral effect could be also mediated by the modulation of 
gut microbiota. Indeed, we observed several modifications of faecal 
microbial communities and, in particular, a variation in amount of 
Firmicutes and Bacteroidetes in BTBR mice upon PEA treatment. A marked 
augment of Firmicutes, mainly due to the increase of Unclassified genus of 
Clostridiales, to the expense of Bacteroidetes, is the most evident change 
induced by PEA administration. Clostridia include the majority of species 
able to produce butyrate as metabolic product of anaerobic fermentation. 
Indeed, it has been demonstrated  the key role of butyrate in the maintenance 
of gut physiology, regulating gut barrier permeability, suppressing 
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inflammation and modulating immune functions (250). Although further 
studies are needed, here, we demonstrated that PEA modulated gut bacterial 
species composition, whose remodelling may be associated to gut 
homeostasis. 
In conclusion, PEA showed beneficial effects on complex disorders such as 
ASDs, due to its pleiotropic mechanism of action, evidenced by 
neuroprotection, anti-inflammatory effects, and the modulation of gut-brain 
axis, through restoring gut integrity and remodelling gut microbiota 
composition. 
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6.2. PEA and obesity-induced depression 
 
MDD and obesity represent often two inter-related burdens. These two 
disorders are strictly interconnected, composing a bi-directional axis, 
although the description of underlying mechanisms is not completely 
clarified (251). Several clinical studies demonstrated that obesity is 
prospectively associated to the onset of MDD, highlighting a significant 
obesity-to-depression association (168). In the last part of this PhD 
programme, we investigated the effects induced by high fat feeding in the 
onset of depressive episodes, elucidating biomolecular mechanisms that 
combine the two sides of the same coin. Furthermore, we assessed PEA 
improvement of this pathological condition induced by HFD overnutrition. 
Recently, Wu et al. (252) demonstrated that young mice on HFD for 6 
weeks, showed depressive-like behaviour associated to an impairment of 
hippocampal neurogenesis, due to a reduction of phosphorylated CREB and 
BDNF expression. Here, after 19 weeks of HFD, mice exhibited a depressive 
mood, evidencing by an increased immobility time in FST and TST and an 
impairment of CREB/BDNF pathway in hippocampus. The treatment with 
PEA induced a significant improvement in depressive state with a 
restoration of hippocampal BDNF signalling. These findings reinforced 
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previous preliminary data where a single administration of PEA in mice at 
different dosage reduced immobility time in FST and TST more than the 
anti-depressant drug fluoxetine (92). 
As previously demonstrated, high fat diet feeding is characterized by 
increased levels of circulating LPS, pro-inflammatory cytokines and 
chemokines (253). Consistently, here we showed an alteration of serum 
inflammatory and metabolic profile, restored by PEA treatment. All 
detrimental factors elevated in the bloodstream, could reach the 
hypothalamus and cross BBB, mainly in areas where barrier integrity is 
more rarefied, such as ARC, a zone involved not only in the regulation of 
food intake, but also in the modulation of cognitive function through the 
connection with other brain areas (mesolimbic dopamine system, 
hippocampus, orbitofrontal cortex, nucleus accumbens, striatum and 
prefrontal cortex) (254). The occurrence of these detrimental molecules in 
ARC induces an impairment of anorexigen POMC neurons, whose 
dysfunction precedes inflammation and represents a leading factor for the 
progression of obesity (255). Moreover, in obese mice, HFD can induce 
neuroinflammation, characterized by microglial infiltration, activation and 
proliferation; activation of the pro-inflammatory transcription factor NF-kB; 
and increased expression of pro-inflammatory cytokines (256-259). 
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Here, we demonstrated that HFD caused a decreased activation of POMC 
neurons in ARC accompanied by microglial activation addressed by IBA-1 
increased expression. In addition, in hypothalamus from HFD mice we 
found an alteration of inflammatory mediators and a reduced transcription 
of the neurotrophin BDNF. Interestingly, PEA treatment restored POMC 
neuron activation and limited the neuroinflammation. 
The disruption of internal hypothalamic circuitry can lead to the dysfunction 
of other brain regions, such as hippocampus, through defective outputs. The 
loss of hippocampal integrity and function induced by HFD represents 
another pivotal factor that induces the progression of MDD (260). Lu et al. 
(261) demonstrated that 20 week-HFD feeding caused a hippocampal 
inflammation mediated by IKKB/NF-kB activity and production of several 
pro-inflammatory players, such as TNF-a, COX-2 and iNOS. This 
deleterious condition also leads to the loss of BBB integrity, triggering 
further neuroinflammation and activating a vicious self-feeding loop (262). 
In our experimental condition, HFD mice showed an impairment of BDNF 
signaling, an occurrence of inflammation and loss of hippocampal tight 
junctions, such as zonuline-1 and occludin. The treatment with PEA 
improved this pathological condition, restoring the functionality and 
integrity of hippocampus. 
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Hippocampus and prefrontal cortex interplay mainly for prolonged process 
by which new memories are converted into permanent storehouse of 
knowledge (263). The difficulty in recognizing the old object by HFD mice 
during NORT, prompted us to examine the possible impairment of 
BDNF/CREB pathway in prefrontal cortex. 19-week HFD was able to 
reduce the expression of these parameters, confirming a previous study 
where the exposure to HFD led to detrimental effect on prefrontal cortex 
function (264). Consistently with the improvement in recognition activity, 
PEA was able to restore the levels of BDNF and its signaling pathway in 
prefrontal cortex of HFD mice. 
In last years, several studies have demonstrated the presence of PPARα in 
hippocampus, more than other brain areas. This receptor plays a pivotal role 
in the modulation of synaptic function, through the up-regulation of the 
transcription factor CREB. Indeed, in PPARα KO, but not PPARβ KO mice, 
CREB was down-regulated and a decreased spatial learning and memory 
was shown (64). Moreover, the same group demonstrated also that statin-
mediated nuclear activation of PPARα modulated the expression of 
neurotrophins in different brain cells (265). Yang et al. (266) showed the 
antidepressive effect of PPARα agonist, WY-14643, in improving BDNF 
signaling pathway both in hippocampus and prefrontal cortex, and 
preventing neuroinflammation and oxidative-nitrosative stress in the mouse 
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model of lipopolysaccharide-induced depression. PEA, as a PPARα agonist, 
stimulate the expression of PPARα, its coactivator PGC1α and the 
downstream FGF21, parameters altered by HFD, indicating a possible role 
of PPARα in ameliorating the obesity-induced depression. 
Potential neurobehavioral disruptions following exposure to HFD may be 
mediated by gut microbiota alterations, i.e. through the gut-microbiome-
brain axis. HFD-fed mice treated with PEA showed mild changes in the 
composition of the gut microbiota compared to HFD fed mice: in particular 
Desulfovibrio was reduced by PEA treatment, while U.g. of Clostridiaceae 
and Dehalobacterium were increased. Studies have demonstrated a 
significant increase in Desulfovibrionaceae, potential endotoxin producers, 
in the gut microbiomes of both HFD-induced obese mice and obese human 
subjects compared with lean individuals (267-269). Here, HFD-fed mice 
treated with PEA showed a decrease in endotoxin-producing Desulfovibrio 
bacteria, whose increase has been positively correlated with obesity and 
inflammation. The significant reduction in the relative abundance of this 
endotoxin-producing opportunistic pathogens Desulfovibrio by PEA is 
indeed also consistent with a possible concomitant reduction in 
endotoxemia, whose increase correlates with depression mood. 
On the other hand, we have found a marked increase of an U.g. of 
Clostridiaceae, belonging to Clostridiales, by PEA treatment. This 
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modification is consistent with what we have already shown in BTBR mice, 
suggesting a peculiar effect of PEA in increasing Clostridiales genus relative 
abundance, and consistently Clostridiales-producing metabolites. In 
particular, an increase in SCFAs could be hypothesized, also considering the 
beneficial effect they exert in gut homeostasis. Moreover, among SCFAs, 
butyrate has been shown to counteract LPS-induced depressive state in mice, 
an effect related to decreased IBA-1 hippocampal expression (270). Finally, 
we have shown a reduction of Dehalobacterium genus in HFD-fed mice. 
Actually, Javurek et al in 2017 (271), have correlated this alteration with 
behavioural modifications. Indeed, we have also reported that the reduction 
in this genus was found in BTBR mice, where the autistic phenotype was 
also accompanied by leaky gut and inflammation. These preliminary data on 
PEA-induced gut microbiota remodelling need further investigation, 
however suggest a novel possible peripheral mechanism underlying not only 
gut homeostasis but also all related-ailments profoundly modulated by gut-
brain axis. 
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Highlights 
 
Ø Autistic mice turned gut homeostasis upside down, showing a 
pronounced dysbiosis, the loss of its barrier integrity and 
inflammation. 
Ø PEA limited stereotyped behavior and improve social interaction of 
autistic mice, through the reduction of inflammation and the 
modulation gut microbiota. 
Ø High fat diet feeding induced a depressive-like behavior in mice 
triggered by an extent neuroinflammation and gut dysbiosis. 
Ø PEA improved depressive behavior and memory deficit induced by 
HFD, improved BBB integrity, reducing hypothalamic, hippocampal 
and cortical inflammation and modulating microbiota composition. 
Ø All the effects of PEA were contingent to PPAR-a activation. 
 
  
135 
 
General conclusions: PEA and CNS disorders 
 
In the light of obtained data, we can hypothesise that systemic administration 
of PEA could directly impact neuroinflammation, being able to cross the 
BBB, but also indirectly reduce peripheral inflammatory input to the brain, 
through its anti-inflammatory properties at colonic and systemic level. 
Therefore, our hypothesis is that PEA would reduce the trafficking of 
inappropriate gut-derived detrimental factors into the portal circulation and 
the crossing through a permissive BBB, leading to a reduction in systemic 
and ultimately central inflammation. 
In conclusion, PEA may be considered a multifunctional compound for an 
integrative and innovative approach against complex diseases, such as 
metabolic illness and CNS disorders, due to its pleiotropic mechanism of 
action, supporting neuroprotection, anti-inflammatory effects, and the 
modulation of gut-brain axis, through restoring gut integrity and remodeling 
gut microbiota composition. 
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